quinazolines has been researched along with Benign Neoplasms, Brain in 479 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.42) | 18.2507 |
| 2000's | 142 (29.65) | 29.6817 |
| 2010's | 308 (64.30) | 24.3611 |
| 2020's | 27 (5.64) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, Q; Ma, S; Mao, Y; Yin, W; Yu, Q; Zhang, K; Zhao, R | 2 |
| Ballman, KV; Blinder, V; Borges, VF; Carey, LA; Goetz, MP; Irvin, WJ; Kommalapati, A; Krop, I; Lee, M; McCall, L; Mitchell, M; O'Sullivan, CC; Partridge, AH; Symmans, WF; Tung, NM; Weiss, A; Zemla, T | 1 |
| Ansari, K; Bhan, A; Chen, MY; Jandial, R | 1 |
| Esmaeili, F; Ghaffari, SH; Hamzehlou, S; Irani, S; Kashani, B; Momeny, M; Mousavi, SA; Shamsaiegahkani, S; Yousefi, H | 1 |
| Borges, V; Cameron, D; Carey, LA; Curigliano, G; Feng, W; Gelmon, K; Hamilton, E; Hortobagyi, GN; Hurvitz, S; Krop, I; Loi, S; Loibl, S; Mueller, V; Murthy, R; Okines, A; Paplomata, E; Pegram, M; Ramos, J; Slamon, D; Winer, E | 1 |
| Bachelot, T; Bailleux, C; Darlix, A; Jacot, W | 1 |
| Ahmed, AU; Balyasnikova, IV; Burga, R; Castro, B; Cordero, A; Fares, J; Kanojia, D; Lee-Chang, C; Lesniak, MS; Miska, J; Petrosyan, E; Ramsey, MD; Rashidi, A; Schwartz, CW; Xiao, T; Zhang, P | 1 |
| Burgenske, DM; Dragojevic, S; Elmquist, WF; Mladek, AC; Oh, JH; Sarkaria, JN; Talele, S; Zhang, W | 1 |
| Badwe, R; Bajpai, J; Bhargava, P; Budrukkar, A; Desai, S; Ghosh, J; Gulia, S; Gupta, S; Joshi, S; Kannan, S; Nair, N; Pathak, R; Patil, A; Popat, P; Rath, S; Rathnasamy, N; Sarin, R; Shenoy, R; Shet, T; Wadasadawala, T | 1 |
| Daga, H; Fujisaka, Y; Hattori, Y; Ikeda, N; Iwamoto, Y; Katakami, N; Kozuki, T; Morita, S; Nakagawa, K; Nishino, K; Oguri, T; Okamoto, T; Oki, M; Sato, Y; Sugawara, S; Takahashi, T; Urata, Y; Yamamoto, N; Yokoyama, T | 1 |
| Antao, V; Lamarre, N; Montemurro, F; Peña-Murillo, C; Sanglier, T; Shim, J | 1 |
| Aydiner, A; Dogan, I; Ibis, K; Kizildag, I; Özkurt, S; Saip, P; Vatansever, S | 1 |
| Bellio, H; Desmoulins, I; Ladoire, S; Méjean, N; Truntzer, C | 1 |
| Chen, S; Li, D; Li, J; Liu, Q; Wang, L; Zhao, J | 1 |
| Abdulkarim, B; Daniel, P; Duncan, HM; Eppert, K; Guiot, MC; Jean-Claude, B; Lauzon, N; Meehan, B; Petrecca, K; Rak, J; Sabri, S; Schmitt, J; Sharifi, Z | 1 |
| Abramson, V; Anders, C; Bachelot, T; Bedard, PL; Borges, V; Braga, S; Cameron, D; Carey, LA; Curigliano, G; Duhoux, FP; Feng, W; Gelmon, K; Greil, R; Hamilton, E; Hortobagyi, G; Hurvitz, SA; Jakobsen, E; Krop, I; Lin, NU; Loi, S; Loibl, S; Müller, V; Murthy, RK; Okines, A; Oliveira, M; Palanca-Wessels, MC; Paplomata, E; Pegram, M; Shachar, SS; Slamon, D; Walker, L; Winer, EP | 1 |
| Arimura, A; Baird, RD; Bonneterre, J; Campone, M; Cresti, N; Garcia-Corbacho, J; Italiano, A; Macpherson, IR; Posner, J; Rafii, S; Saggese, M; Spicer, J; Spiliopoulou, P; Takeda, Y | 1 |
| Bai, L; Bai, R; Chen, N; Cui, J; Han, F; Li, J; Li, W; Qian, L; Yu, Y; Zhao, Y | 1 |
| Ahn, JS; Ahn, MJ; Ku, BM; La Choi, Y; Lee, J; Lee, SH; Park, K; Shim, JH; Sun, JM | 1 |
| Gangemi, E; Greco, C; Ippolito, E; La Cesa, A; Matteucci, P; Ramella, S; Santini, D; Santo, B; Silipigni, S | 1 |
| Barry, WT; Freedman, RA; Krop, I; Lawler, E; Leone, JP; Li, T; Lin, NU; Metzger Filho, O; Tan-Wasielewski, Z; Tolaney, SM; Trippa, L; Walker, L; Winer, EP; Younger, J | 1 |
| Abramson, V; An, X; Anders, C; Bachelot, T; Bedard, PL; Borges, V; Cameron, D; Carey, L; Chien, AJ; Conlin, A; Curigliano, G; DiGiovanna, MP; Gelmon, K; Hamilton, E; Hurvitz, S; Lin, NU; Loi, S; Loibl, S; Mayor, J; McGoldrick, S; Mueller, V; Murthy, RK; O'Regan, R; Okines, A; Oliveira, M; Paplomata, E; Wardley, A; Winer, EP; Zelnak, A | 1 |
| Chen, M; Chen, W; Han, G; Jiang, Y; Mao, S; Shi, N; Yu, W; Zhang, X | 1 |
| Bambini, V; Brunetto, AT; de Farias, CB; Freire, NH; Jaeger, M; Metcalfe, VA; Pinheiro, KV; Roesler, R; Shaw, L; Smith, CGS; Souza, BK; Thomaz, A | 1 |
| Deng, Z; Du, Z; Li, X; Tao, Z; Wang, H; Zhou, Y | 1 |
| Godoy, PRDV; Lima, SCG; Montaldi, AP; Sakamoto-Hojo, ET; Xavier, DJ | 1 |
| Curigliano, G; Prat, A; Tarantino, P | 1 |
| Exman, P; Tolaney, SM | 1 |
| Borsellino, N; Galanti, D; Gori, S; Incorvaia, L; Inno, A; La Vecchia, M; Russo, A | 1 |
| Fan, Y; Fang, L; Gong, L; Han, N; Huang, Z; Lu, H; Qin, J; Qiu, G; Xie, F; Xu, Y | 1 |
| Breunig, JJ; Chan, SL; Chen, Y; Ching, J; Ding, LW; Doan, N; Dutra-Clarke, M; Hazawa, M; Jiang, YY; Koeffler, HP; Kovalik, JP; Lin, DC; Madan, V; Mayakonda, A; Müschen, M; Said, JW; Savinoff, SE; Tyner, JW; Watkins, A; Xu, L; Yang, H; Yong, WH | 1 |
| He, H; He, X; Lan, BH; Li, MX; Li, RQ; Liu, GD; Ruan, ZH; Wang, G; Wu, Y; Xiao, HL; Yang, ZZ; Zhang, ZM; Zhu, B; Zhu, YX | 1 |
| Chen, JS; Chen, KY; Chih-Hsin Yang, J; Ho, CC; Liao, WY; Lin, CC; Lin, ZZ; Shih, JY; Yao, ZH; Yu, CJ | 1 |
| Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A | 1 |
| Bobos, M; Christodoulou, C; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeras, KT; Karavasilis, V; Kouvatseas, G; Papadopoulos, G; Papandreou, CN; Rallis, G; Razis, E; Samantas, E; Syrigos, KN; Varaki, K | 1 |
| Chen, G; Cheng, Y; Feng, J; Hu, C; Huang, C; Huang, Y; Liu, X; Lu, S; Song, Y; Tan, FL; Wu, G; Wu, YL; Yan, HH; Yang, JJ; Zhang, L; Zhong, W; Zhou, C | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghidini, M; Ghilardi, M; Lonati, V; Petrelli, F; Tomasello, G | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Kato, T; Ogura, T; Okudela, K; Sekine, A; Yamakawa, H; Yamanaka, Y | 1 |
| Arqués, O; Cedrés, S; Fasani, R; Felip, E; Guillaumet-Adkins, A; Heyn, H; Martinez de Castro, A; Martinez-Marti, A; Matito, J; Mereu, E; Miquel, JM; Nadal, E; Navarro, A; Nuciforo, P; Palmer, HG; Pardo, N; Remon, J; Rodriguez-Esteban, G; Villanueva, A; Vivancos, A | 1 |
| Fang, YF; Hsu, PC; Kao, KC; Li, SH; Liu, CY; Tseng, LC; Wang, CC; Yang, CT | 1 |
| Gao, XX; Han, B; Jiang, ZM; Li, C; Wang, P; Wang, XH; Yang, RF; Yu, B; Zhang, L; Zhang, RQ; Zhang, Y | 1 |
| Haeno, H; Michor, F; Stein, S; Vivanco, I; Zhao, R | 1 |
| Hirata, M; Nezasa, KI; Shinonome, S; Tanaka, H; Tanaka, Y; Torii, M | 1 |
| Li, X; Wang, J; Wang, Y; Xing, L; Yang, Z; Yu, J; Zhang, T; Zheng, L | 1 |
| Gao, F; Jiang, AY; Luo, HL; Lv, YF; Zhang, J | 1 |
| Duchnowska, R; Jassem, J; Loibl, S | 1 |
| Aarons, L; Martin, EC; Yates, JWT | 1 |
| Harter, PN; Mittelbronn, M; Pietsch, T; Reuter, D; Ronellenfitsch, MW; Senft, C; Steinbach, JP; Urban, H; Westphal, M; Zeiner, PS | 1 |
| Lin, M; Yao, Z; Zhang, C; Zhao, N | 1 |
| Gao, H; Hu, C; Liu, R; Qin, L; Su, D; Wang, G; Yang, C; Yang, X; Yang, Y; Yu, M; Zhou, Y | 1 |
| Gupta, P; Mukhopadhyay, CK; Pandey, HS; Seth, P; Singh, P | 1 |
| Ikeuchi, T; Ishikawa, S; Tokuyasu, H | 1 |
| Chen, K; Colclough, N; Fridén, M; Johnström, P; McGinnity, DF | 1 |
| Chen, J; Wang, J | 1 |
| Jin, B; Liu, J; Liu, Y; Qu, X; Su, H | 1 |
| Inoue, H; Ishikawa, T; Kajimoto, Y; Kuroiwa, T; Miyatake, S; Sun, W | 1 |
| Kümler, I; Larsen, PB; Nielsen, DL | 1 |
| Hayashi, N; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Masuda, N; Nagashima, Y | 1 |
| Akhavan, D; Babic, I; Bensinger, SJ; Cavenee, WK; Cloughesy, TF; Dang, J; Flagg, M; James, CD; Kornblum, HI; Mischel, PS; Nael, A; Nathanson, D; Nourian, AA; Pourzia, AL; Sasayama, T; Tamanoi, F; Tanaka, K; Villa, GR; Vinters, HV; Williams, KJ; Yang, H; Yong, WH | 1 |
| Han, S; He, QH; Li, P; Liu, KY; Liu, XJ; Liu, XX; Liu, YN; Ma, SH; Qin, JZ; Shen, L; Wu, WH; Wu, WT; Yin, F; Zhang, JM; Zhang, XY | 1 |
| Ahmed, S; Ammannagari, N; Bravin, EN; Patel, A | 1 |
| Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS | 1 |
| Boult, JK; Bradley, DP; Robinson, SP; Terkelsen, J; Walker-Samuel, S | 1 |
| Beriwal, S; Flickinger, JC; Vargo, JA | 1 |
| Batchelor, TT; de Groot, J; Reardon, DA | 1 |
| Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Gallo, JM; Lv, H; Sharma, J | 2 |
| Azria, D; Braccini, AL; Ferrero, JM; Jacot, W; Romieu, G; Thezenas, S | 1 |
| Grossman, S; Mehta, M; O'Neill, A; Robins, HI | 1 |
| Sperduto, PW | 1 |
| Kathagen, A; Kolbe, K; Lamszus, K; Liffers, K; Merlo, A; Riethdorf, S; Schulte, A; Westphal, M; Zapf, S | 1 |
| Bhatt, VR; Ganti, AK; Kedia, S; Kessinger, A | 1 |
| Chamberlain, MC | 1 |
| Gorbunova, VA; Moskvina, EA; Naskhletashvili, DR | 1 |
| Aldape, KD; Ding, Z; Guo, H; Huang, S; Huang, WC; Lowery, FJ; Sahin, AA; Steeg, PS; Wang, H; Yu, D; Zhang, C; Zhang, L; Zhang, S | 1 |
| Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J | 1 |
| Brown, PD; Komaki, R; McGovern, SL; Soh, HE; Wefel, JS; Welsh, JW | 1 |
| Chen, Y; Wang, M; Zhao, J; Zhong, W | 1 |
| Bachelot, T; Bidard, FC; Campone, M; Cropet, C; Curé, H; Dalenc, F; Dômont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Mahier Aït-Oukhatar, C; Pierga, JY; Romieu, G; Tresca, P | 1 |
| Awada, A; Buttice, A; Cardoso, F; D'Hondt, V; de Azambuja, E; Devriendt, D; Gil, T; Lalami, Y; Lebrun, F; Lemort, M; Moulin, C; Paesmans, M; Piccart-Gebhart, M; Rossari, J; Sotiriou, C; Zardavas, D | 1 |
| Hasegawa, Y; Hatano, K; Iizasa, T; Itakura, M; Iuchi, T; Kageyama, H; Kawasaki, K; Nagano, O; Sakaida, T; Shingyoji, M; Yokoi, S | 1 |
| Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S | 1 |
| Fishbein, M; Marchevsky, A; Reckamp, KL; Saldivar, JS; Scher, KS | 1 |
| Agar, JN; Agar, NY; Alberta, J; Davis, E; Easterling, ML; Ebling, MC; Ide, JL; Kellersberger, KA; Kesari, S; Liu, X; Marchionni, MA; Norton, I; Santagata, S; Sauvageot, CM; Stiles, CD; Stuart, DD; Wang, LY | 1 |
| Pang, Q; Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E | 2 |
| Bastida, CC; Falchook, GS; Jiang, Y; Kurzrock, R; Moulder, SL; Wheler, JJ | 1 |
| Ancukiewicz, M; Batchelor, TT; Chi, AS; Dietrich, J; Duda, DG; Eichler, AF; Emblem, KE; Gerstner, ER; Hochberg, FH; Iafrate, AJ; Ivy, SP; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Loeffler, JS; Lu-Emerson, C; Pinho, MC; Plotkin, SR; Polaskova, P; Rosen, BR; Snuderl, M; Sorensen, AG; Wen, PY | 1 |
| Bellon, JR; Come, SE; Eichler, AF; Eisenberg, E; Freedman, RA; Gelman, RS; Harris, GJ; Henderson, MA; Ligibel, JA; Lin, NU; Macdonald, SM; Mahadevan, A; Mayer, EL; Moy, B; Ramakrishna, N; Storniolo, AM; Winer, EP; Younger, J | 1 |
| Chishima, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kita, K; Narui, K; Sasaki, T; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yoneyama, S | 1 |
| Song, Z; Zhang, Y | 1 |
| Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY | 1 |
| Homicsko, K; Hottinger, AF; Stupp, R | 1 |
| Cao, S; Chen, C; Chen, J; Gao, H; Jiang, X; Xi, Z; Zhang, Q | 1 |
| Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Drappatz, J; Gilbert, MR; Groves, MD; Kuhn, JG; Lamborn, KR; Lieberman, FS; Ligon, AH; Ligon, KL; Mehta, MP; Norden, AD; Prados, MD; Robins, HI; Santagata, S; Wen, PY; Wright, JJ; Yung, WK | 1 |
| Şendur, MA; Uncu, D; Zengin, N | 1 |
| Butowski, NA; Chang, SM; Clarke, JL; Costello, JF; DeSilva, AA; Molinaro, AM; Perry, A; Phillips, JJ; Prados, MD; Rabbitt, JE | 1 |
| Cardinali, B; Crinò, L; Del Mastro, L; Foglietta, J; Gori, S; Inno, A; Lunardi, G | 1 |
| Beal, K; Chan, TA; Gerber, NK; Riely, GJ; Rimner, A; Shi, W; Wu, AJ; Yamada, Y; Yu, HA; Zhang, Z | 1 |
| Cao, KI; Kirova, YM | 1 |
| Chamberlain, MC; Fadul, CE; Grimm, S; Kim, L; Phuphanich, S; Recht, L; Rosenfeld, S; Zhu, JZ | 1 |
| Dziadziuszko, R; Peters, S; Zimmermann, S | 1 |
| Feng, D; Hu, Q; Li, H; Ma, H; Su, Y; Tao, H; Wang, X; Zhang, C | 1 |
| Addeo, R; Caraglia, M; Parlato, C; Zappavigna, S | 1 |
| Meng, X; Sun, X; Yu, J; Zhang, J | 1 |
| Kaminska, B; Maleszewska, M; Steranka, A | 1 |
| Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S | 1 |
| Balyan, R; Lockman, PR; Morikawa, A; Murphy, CG; Peereboom, DM; Samala, R; Seidman, AD; Simmons, A; Smith, QR; Steeg, PS; Tabar, V; Thorsheim, HR; Weil, RJ | 1 |
| Bates, A; Counsell, N; Faivre-Finn, C; Hackshaw, A; Lee, SM; Lewanski, CR; Ngai, Y; Ottensmeier, C; Patel, N; Wadsworth, C | 1 |
| Altundag, K; Arslan, C; Dizdar, O | 2 |
| Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S | 1 |
| Arai, M; Hayashihara, K; Iwasawa, T; Kato, T; Ogura, T; Ohashi, K; Okudela, K; Saito, T; Satoh, H; Sekine, A; Tamura, K | 1 |
| Dickgreber, NJ; Hoffknecht, P; Maria Huber, R; Märten, A; Pelzer, T; Schütz, M; Serke, M; Stöhlmacher-Williams, J; Tufman, A; Wehler, T; Wiewrodt, R | 1 |
| Shawky, H; Tawfik, H | 1 |
| Brown, D; Butowski, N; Cheng, SY; Giles, FJ; James, CD; Mazar, AP; Nicolaides, T; Ozawa, T; Parsa, AT; Raizer, JJ; Sarkaria, JN; Shen, W; Stegh, AH; Yao, TW; Yoshida, Y | 1 |
| Chen, S; Hao, Y; Li, B; Li, L; Liu, C; Ning, F; Wang, F; Yu, Z | 1 |
| Cavenee, WK; Furnari, FB; Gonias, SL; Hu, J; Muller, KA; VandenBerg, SR | 1 |
| Chang, SM; Clarke, J; Jalilian, L; Lupo, JM; Molinaro, AM; Nelson, SJ; Prados, M; Wen, Q | 1 |
| Cavenee, WK; Chen, CC; Furnari, FB; Gomez, GG; Gonias, SL; Hu, J; Mischel, PS; Pizzo, D; Taylor, T; Thorne, AH; VandenBerg, SR; Villa, GR; Wykosky, J | 1 |
| Chen, H; Du, N; Li, F; Yang, P; Zhao, X; Zhu, G | 1 |
| Gillespie, GY; Lobo, MR; Pike, MM; Wang, X; Woltjer, RL | 1 |
| Batchelor, TT; Beroukhim, R; Betensky, RA; Chheda, MG; Chi, AS; Drappatz, J; Eichler, AF; Gerstner, ER; Hochberg, FH; Norden, AD; Wen, PY; Yang, D | 1 |
| Fujisawa, T; Hayashi, N; Honda, Y; Hozumi, Y; Ishida, M; Iwata, H; Kanbayashi, C; Kondo, N; Masuda, N; Matsui, A; Naito, Y; Nakamura, R; Niikura, N; Oshitanai, R; Saji, S; Takashima, S; Tsuneizumi, M; Watanabe, K; Yamauchi, H; Yasojima, H | 1 |
| Patil, A; Sherbet, GV | 1 |
| Bai, Y; Cheng, Z; Li, S; Lv, J; Xie, L; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhong, W | 1 |
| Dittrich, C; Fridrik, MA; Gampenrieder, SP; Greil, R; Hufnagl, C; Lang, A; Mlineritsch, B; Petru, E; Pircher, M; Ressler, S; Rinnerthaler, G; Thaler, J; Ulmer, H; Weltermann, A | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Marchetti, D; Ngo, JA; Wetzel, MD; Zhang, L | 1 |
| Hara, A; Iwama, T; Kunisada, T; Park, DM; Soeda, A; Yoshimura, S | 1 |
| Ikegami, Y; Inoue, Y; Ishikawa, T; Kajimoto, Y; Kuroiwa, T | 1 |
| Bachelot, T; Bernard-Marty, C; Bonneterre, J; Conforti, R; Le Rhun, E; Taillibert, S | 1 |
| Foltz, G; Harrison, JK; Hothi, P; Law, BK; Luo, D; Pham, K; Reynolds, BA; Siemann, DW | 1 |
| Batchelor, TT; Duda, DG; Emblem, KE; Gerstner, ER; Jain, RK; Loeffler, JS; Lu-Emerson, C; Taylor, JW | 1 |
| Bartsch, R; Bergen, ES; Berghoff, AS; Preusser, M; Rudas, M | 1 |
| Biganzoli, L; Dambrosio, M; Minelli, M; Molteni, L; Montemurro, F; Mustacchi, G; Pronzato, P; Scaltriti, L | 1 |
| Alimoghaddam, K; Estiar, MA; Ghaffari, SH; Ghavamzadeh, A; Modarressi, MH; Yaghmaie, M; Zekri, A | 1 |
| Chen, LK; Dinglin, XX; Liang, JZ; Liao, H; Ma, SX; Qin, T; Wei, WD; Xu, F; Zeng, YD; Zhang, L | 1 |
| Kortmann, RD; Seidel, C | 1 |
| Canoll, P; Chen, S; Guo, B; Horner, JW; Klingler, S; Paik, JH; Vaseva, AV; Wang, YA; Yan, H; Yao, J; Ying, H; Zhang, L; Zheng, H | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Aljohani, H; Bahassi, el M; Koncar, RF; Lee, SH; Park, BS; Zarzour, A | 1 |
| Ali, SM; Berry, J; Cascone, T; Guha-Thakurta, N; Heymach, JV; McMahon, C; Miller, V; Pai, S; Roxas, M; Subbiah, IM; Subbiah, V; Tang, Z | 1 |
| Arpaci, E; Arslan, UY; Artac, M; Bayoglu, IV; Demirci, U; Dogan, M; Guler, T; Isikdogan, A; Koca, D; Kucukoner, M; Kucukzeybek, Y; Oguz, A; Turker, I; Uncu, D; Zengin, N | 1 |
| Ahluwalia, MS; Batchelor, TT; Duda, DG; Gerstner, ER; Grossman, S; Jain, RK; Kaley, TJ; Levine, MA; Mikkelsen, T; Nabors, BL; Olson, JJ; Wen, PY; Ye, X | 1 |
| Fang, L; Li, F; Lin, N; Song, Y; Weng, X; Xu, Y | 1 |
| Chang, SN; Hsu, KH; Lin, CH; Pan, HC; Sheehan, J; Sheu, ML; Tsou, HK | 1 |
| Chen, L; Chen, X; Luo, S; Xie, X | 1 |
| Hata, A; Katakami, N | 1 |
| Fan, Y; Fang, L; Gong, L; Huang, Z; Lei, T; Mao, W; Miao, L; Yang, H; Yu, H | 1 |
| Bi, Z; Jiang, Y; Li, D; Liu, Y | 1 |
| Bandai, Y; Ijichi, M; Kusaka, K; Sakata, H; Shibasaki, M; Tanabe, A; Toda, T | 1 |
| Cima, MJ; Hochberg, FH; Ong, Q | 1 |
| Adamo, V; Ferraro, G; Franchina, T; Giordano, A; Picone, A; Ricciardi, GR; Russo, A; Toscano, G; Zanghì, M | 1 |
| Fang, L; Li, F; Lin, N; Ma, S; Song, Y; Sun, X; Xu, Y; Zhang, Y | 1 |
| Chen, K; Cheng, Z; Johnström, P; Li, DY; Varnäs, K; Wang, J; Yang, ZF; Zeng, Q; Zhang, X | 1 |
| Esteva, FJ; Teplinsky, E | 1 |
| Adamczyk, A; Bojko, A; Cierniak, A; Ligeza, J | 1 |
| Liu, X; Shi, Y; Xu, J; Yang, S; Zhang, X | 1 |
| Dikomey, E; Gal, A; Grob, TJ; Kriegs, M; Lamszus, K; Petersen, C; Rieckmann, T; Riedel, M; Rothkamm, K; Schulte, A; Struve, N | 1 |
| Alshami, J; Cseh, A; Gibson, N; Guiot, MC; Kavan, P; Muanza, T; Owen, S; Reardon, DA; Solca, F | 1 |
| Amoresano, A; Camorani, S; Carpentieri, A; Cerchia, L; Chiariello, M; Colecchia, D; Crescenzi, E; Fedele, M | 1 |
| Fang, YF; Hsieh, MH; Li, SH | 1 |
| Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M | 1 |
| Iwasa, T; Kaneda, H; Nakagawa, K; Nonagase, Y; Okamoto, K; Shimizu, T; Takeda, M; Tanaka, K; Tsurutani, J; Yoshida, T | 1 |
| Lin, NU | 1 |
| Bachelot, T; Barriere, J; Bono, P; Ciruelos, E; Cortés, J; Dieras, V; Espié, M; Hurvitz, S; Joensuu, H; Kellokumpu-Lehtinen, PL; Kim, SB; Le Rhun, E; Nabholtz, JM; Ould-Kaci, M; Piacentini, F; Ro, J; Roux, F; Schneeweiss, A; Sohn, JH; Taguchi, J | 1 |
| Gillespie, GY; Grafe, MR; Kukino, A; Lobo, MR; Pike, MM; Schabel, MC; Springer, CS; Tran, H; Woltjer, RL | 1 |
| Chonan, M; Narita, N; Tominaga, T | 1 |
| Hirsh, V; Massey, D; Mok, T; O'Byrne, K; Popat, S; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC; Zazulina, V | 1 |
| Butman, JA; Fine, HA; Iwamoto, FM; Kreisl, TN; Odia, Y; Shih, JH; Sul, J | 1 |
| Griggs, JJ; Hayes, DF; Henry, NL; Kidwell, KM; Merajver, SD; Murthy, P; Schott, AF; Smerage, JD; Van Poznak, CH; Wicha, MS | 1 |
| Dermawan, JK; Gurova, KV; Hitomi, M; Lathia, JD; Purmal, AA; Rich, JN; Sandlesh, P; Silver, DJ; Sloan, AE; Stark, GR; Venere, M; Wu, Q | 1 |
| Huo, LM; Sun, HT; Tian, JH; Xu, JG; Yang, G; Yang, KH; Zhang, P; Zheng, MH | 1 |
| Jiang, T; Jiang, X; Pang, X; Pang, Z; Wan, X; Xu, W; Zhang, Q; Zhang, Z; Zhao, J; Zheng, X | 1 |
| Battastini, AM; Coelho, BP; de Quadros, AH; Gaelzer, MM; Gonçalves, CA; Guerra, MC; Guma, FC; Hoppe, JB; Salbego, CG; Setton-Avruj, P; Terra, SR; Usach, V | 1 |
| Ding, L; Ding, Z; He, J; Hou, M; Huang, M; Li, L; Liang, M; Liu, Y; Lu, Y; Ren, L; Tan, F; Xiang, J; Xiong, W; Yu, Q; Zhou, L; Zhou, X; Zhu, J | 1 |
| Ballard, P; Box, M; Cantarini, M; Cross, D; Grist, M; Hickey, M; Jänne, PA; Johnström, P; Jordan, A; Kim, DW; Malmquist, J; Pickup, K; Thress, KS; Varnäs, K; Yang, JC; Yang, Z; Yates, JW | 1 |
| Burghuber, OC; Hochmair, M; Holzer, S | 1 |
| Chen, Y; Mu, L; Tang, X; Wang, T; Yuan, Y; Zhao, Y | 1 |
| Batchelor, TT; Chowdhary, S; Desideri, S; Duda, DG; Gerstner, ER; Grossman, S; Lesser, GJ; Peereboom, D; Supko, JG; Wen, PY; Ye, X | 1 |
| Chang, YH; Chien, KH; Hsu, CR; Tai, MC | 1 |
| Andäng, M; Baskaran, S; Claesson-Welsh, L; Elfineh, L; Forsberg-Nilsson, K; Green, LC; Häggblad, M; Johansson, P; Krona, C; Lönnstedt, I; Lundgren, B; Martens, U; Matuszewski, D; Nelander, S; Padhan, N; Schmidt, L; Sintorn, IM; Uhrbom, L; Wee, S; Westermark, B | 1 |
| Collins, L; Corner, C; Goff, M; Gupta, A; Kelly, C; Lester, J; Love, S; Marshall, E; Middleton, MR; Nobes, J; Roberts, C; Salisbury, A; Tysoe, F; Wise, A; Wolstenholme, V; Woodward, M | 1 |
| Chen, Z; Jiang, B; Su, J; Wu, YL; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhou, Q | 1 |
| Hosomi, Y; Kashima, J; Miwa, M; Okuma, Y | 1 |
| Ahn, MJ; Bai, Y; Chen, K; Cheng, Z; Guo, Q; Kim, DW; Rabbie, S; Wang, Y; Xu, Y; Yang, JC; Yang, Z; Yin, X; Zhang, L; Zhang, X | 1 |
| Ciechomska, IA; Jackl, J; Kaminska, B; Przanowski, P; Wojtas, B | 1 |
| Hanaoka, J; Hayashi, H; Iihara, H; Itoh, Y; Kawaguchi, Y; Mizusaki, N; Sugiyama, T | 1 |
| Bachoo, RM; Cho, SK; Hatanpaa, KJ; Humphries, CG; Kim, RS; Kittler, R; Klingler, S; Kollipara, RK; Maher, EA; Mashimo, T; Mickey, B; Nannepaga, S; Piccirillo, S; Raisanen, J; Regmi, N; Singh, DK; Sirasanagandla, S; Sun, Y; Vemireddy, V; Wang, S; Yang, XL; Zheng, H | 1 |
| Benveniste, EN; Dees, KJ; Gibson, SA; Hjelmeland, AB; McFarland, BC; Meares, GP; Nozell, SE; Rajbhandari, R; Rowse, AL | 1 |
| Ahluwalia, MS; Angelov, L; Barnett, GH; Chao, ST; Kotecha, R; Miller, JA; Mohammadi, AM; Murphy, ES; Peereboom, DM; Suh, JH; Vogelbaum, MA | 1 |
| Ahmadinia, L; Alimoghaddam, K; Amanpour, S; Barghi, F; Dardaei, L; Dehpour, AR; Emami, AH; Eyvani, H; Ghaffari, SH; Ghavamzadeh, A; Ghazi-Khansari, M; Gortany, NK; Mirshahvaladi, S; Moghaddaskho, F; Momeny, M; Sabourinejad, Z; Tavangar, SM; Yousefi, H; Zarrinrad, G | 1 |
| Barrett, GM; Cemeus, C; Dimitroulakos, J; Lorimer, IA; Zhao, TT | 1 |
| Altavilla, G; Arrigo, C; Galletti, G; Marabello, G; Picone, G; Pitini, VV; Santarpia, MC; Tomasello, C | 1 |
| Aldape, K; Colman, H; Conrad, C; de Groot, JF; Gilbert, MR; Groves, MD; Hanna, TA; Hess, KR; Ictech, S; Levin, V; Puduvalli, VK; Yung, WK | 1 |
| Braiteh, F; Johnson, FM; Kurzrock, R | 1 |
| Benowitz, S | 1 |
| Bronder, JL; Feigenbaum, L; Gril, B; Herring, JM; Liewehr, DJ; Merino, MJ; Palmieri, D; Rubin, SD; Steeg, PS; Steinberg, SM; Vega-Valle, E | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD | 1 |
| Ferlini, C; Mozzetti, S; Riccardi, A; Riccardi, R; Servidei, T | 1 |
| Ali-Osman, F; Cao, X; Lo, HW; Zhu, H | 1 |
| Belkacémi, Y; Kuten, A | 1 |
| Glantz, M; Melisko, ME; Rugo, HS | 1 |
| Ma, CD; Shen, KW; Shen, ZZ | 1 |
| Fu, Z; Liu, YL; Mu, DB; Song, B; Song, XR; Teng, XP; Wang, H; Wang, XW; Wei, L; Yang, GR; Yu, JM; Zhao, SQ | 1 |
| Chen, C; Gaspar, LE; Kavanagh, BD; Kleinschmidt-De Masters, BK; McCammon, R; Schwer, AL; Stuhr, K | 1 |
| Abrey, LE; Kreisl, TN; Lassman, AB; Lis, E; Mischel, PS; Rosen, N; Scher, HI; Shaffer, D; Teruya-Feldstein, J | 1 |
| David, K; Drappatz, J; Gerard, M; Kesari, S; McNamara, MB; Muzikansky, A; Norden, AD; Phan, P; Ross, A; Wen, PY | 1 |
| Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S | 1 |
| Deng, Q; Ma, S; Xu, Y; Yu, X | 1 |
| Baker, SJ; Broniscer, A; Ellison, DW; Endersby, R; Gajjar, A; Kocak, M; Laningham, FH; Merchant, TE; Morris, EB; Schaiquevich, P; Stewart, CF | 1 |
| Choi, Y; Kim, JE; Kim, SW; Lee, DH; Lee, JS; Suh, C; Yoon, DH | 1 |
| Armand, JP; Baurain, JF; Brandes, AA; Campone, M; Carpentier, AF; Clement, PM; Frenay, M; Gorlia, T; Kletzl, H; Klughammer, B; Kouwenhoven, MC; Kros, JM; Lacombe, D; Rampling, R; Taphoorn, MJ; Tosoni, A; van den Bent, MJ | 1 |
| Gajjar, A; Wright, KD | 1 |
| Blum, JL; Brufsky, A; Christodoulou, C; Ciruelos, E; Dharan, B; Diéras, V; Gori, S; Greil, R; Lin, NU; Liu, MC; Loibl, S; Lossignol, D; Oliva, C; Paoletti, P; Paul, D; Roché, H; Roychowdhury, D; Rubin, SD; Stemmler, HJ; Steplewski, K; Wardley, A; Winer, EP; Yardley, D; Zembryki, D | 1 |
| Ikeda, K; Itoh, S; Matsumoto, F; Ohba, S | 1 |
| JuanYin, J; Kelly, K; Koretsky, A; Munasinghe, J; Shapiro, E; Tracy, K; Zhang, L | 1 |
| Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF | 1 |
| Batchelor, TT; di Tomaso, E; Duda, DG; Duyverman, AM; Farrar, CT; Fukumura, D; Jain, RK; Kamoun, WS; Lacorre, DA; Lahdenranta, J; Ley, CD; Munn, LL; Sorensen, AG | 1 |
| Batchelor, TT; di Tomaso, E; Duda, DG; Gerstner, ER; Ivy, P; Jain, RK; Loeffler, JS; Ryg, PA; Sorensen, AG | 1 |
| Jaén, P; Muñoz-Zato, E; Pérez, B; Truchuelo, M; Vano-Galvan, S | 1 |
| Belanger, K; Easaw, J; Eisenhauer, E; Forsyth, P; Kamel-Reid, S; Mason, W; McIntosh, L; Schaiquevich, P; Stewart, C; Thiessen, B; Tsao, M | 1 |
| Fine, HA; Smith, JA; Yeh, S | 1 |
| Bakker, A; Ferruzzi, P; Ghiron, C; Kremer, A; Lamanna, C; Nievo, M; Rossi, M; Valensin, S | 1 |
| Ancukiewicz, M; Batchelor, TT; Chen, PJ; di Tomaso, E; Duda, DG; Jain, RK; Jennings, D; Lahdenranta, J; Sorensen, AG; Wang, M; Wen, PY; Yeo, P; Zhang, WT | 1 |
| Benedetti, G; Colucci, G; Crinò, L; Galetta, D; Latini, L | 1 |
| Broniscer, A; Christiansen, SR; Panetta, JC; Stewart, CF | 1 |
| Cornet, K; Foss, CA; Goodwin, CR; Kim, J; Lal, B; Laterra, J; Muzamil, S; Pomper, MG; Sang, Y | 1 |
| D'Elia, A; Formichella, AI; Frati, A; Salvati, M | 1 |
| Chin, TM; Wong, AS; Zee, YK | 1 |
| Bravo Marques, JM | 1 |
| Fukui, T; Hatooka, S; Hida, T; Ito, S; Katayama, T; Mitsudomi, T; Onozato, R; Shimizu, J; Suda, K; Sueda, T; Yatabe, Y | 1 |
| Jeibmann, A; Klämbt, C; Paulus, W; Witte, HT | 1 |
| Akerley, W; Compton, P; Huang, JE; Kolb, MM; Langer, CJ; Socinski, MA; Wang, L | 1 |
| Capri, G; Chang, J; Chen, SC; Conte, P; Cwiertka, K; De Placido, S; Jerusalem, G; Jiang, Z; Johnston, S; Kaufman, B; Link, J; Oliva, C; Parikh, R; Preston, A; Ro, J; Rosenlund, J; Schütte, J; Selzer, M; Zembryki, D | 1 |
| Nagai, A; Shiroma, T; Yamaguchi, M | 1 |
| Bonnichon, A; Le Floch, H; Mairovitz, A; Margery, J; Rivière, F; Staub, E; Vaylet, F | 1 |
| Agarwal, N; Ahluwalia, MS; Barnett, GH; Brewer, CJ; Elson, P; Peereboom, DM; Shepard, DR; Stevens, GH; Suh, JH; Toms, SA; Vogelbaum, MA; Weil, RJ | 1 |
| Bedard, PL; de Azambuja, E; Devriendt, D; Lossignol, D; Piccart-Gebhart, MJ; Tomasello, G | 1 |
| Akhavan, D; Bensinger, SJ; Cloughesy, TF; Dang, J; DeAngelis, LM; Guo, D; Hock, MB; Horvath, S; Huang, TT; Iwanami, A; Kofman, AA; Kuga, D; Kuhn, JG; Lin, KY; Mehta, MP; Mellinghoff, IK; Mischel, PS; Prados, MD; Prins, RM; Robins, HI; Soto, H; Vinters, HV; Watson, AD; Wen, PY; Yong, WH; Zhu, S | 1 |
| Inoue, F; Momosaki, N; Morizono, G; Takenaka, T; Tanaka, T; Tomisaki, S | 1 |
| Hammersley, JR; Kanjwal, S; Taj, A | 1 |
| Besse, B; Soria, JC; Vignot, S | 1 |
| Pikó, B | 1 |
| Batchelor, TT; Ciampa, A; Doherty, LM; Drappatz, J; Gerard, M; Kesari, S; Lafrankie, DC; Ligon, KL; Muzikansky, A; Norden, AD; Phan, P; Sceppa, C; Schiff, D; Weiss, SE; Wen, PY; Wong, ET; Young, G | 1 |
| Abrey, LE; Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Abrey, LE; Aldape, KA; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Ali-Osman, F; Cao, X; Keir, S; Lo, HW; Zhu, H | 1 |
| Liao, XB; Liu, JQ; Sun, XL; Wang, YX; Yan, DF; Yan, SX; Yang, JS | 1 |
| Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S | 1 |
| Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A | 1 |
| Ishida, T; Iwasaku, M; Kunimasa, K; Nishiyama, A; Ubukata, S; Yoshioka, H | 1 |
| Boockvar, JA; Edgar, MA; Karampelas, I; Luther, N; Souliopoulos, EP; Souweidane, MM | 1 |
| Butler, JS; Donahue, BR; Huang, Y; Olmez, I; Rubin, P; Xu, Y | 1 |
| Dalhaug, A; Nieder, C | 1 |
| Gao, HJ; Guo, WF; Li, JJ; Li, XY; Liu, B; Liu, XQ; Qu, LL; Tang, CH; Wang, WW; Wang, WX | 1 |
| Batchelor, TT; Chen, PJ; Gerstner, ER; Jain, RK; Sorensen, G; Wen, PY | 1 |
| Chan, AW; di Tomaso, E; Jain, RK; Kamoun, WS; Lahdenranta, J; McClatchey, AI; Plotkin, SR; Wong, HK | 1 |
| Ancukiewicz, M; Batchelor, TT; Benner, T; Chea, H; Cohen, KS; di Tomaso, E; Drappatz, J; Duda, DG; Eichler, AF; Exarhopoulos, A; Gerstner, E; Hochberg, FH; Ivy, P; Jain, RK; Loeffler, JS; Louis, DN; Moses, MA; Plotkin, SR; Sorensen, AG; Wen, PY | 1 |
| Calabrese, C; Carcaboso, AM; Elmeliegy, MA; Juel, SJ; Shen, J; Stewart, CF; Tracey, L; Waters, CM; Zhang, ZM | 1 |
| Calles, A; Custodio, A; Pérez-Segura, P | 1 |
| Ballman, KV; Behrens, RJ; Buckner, JC; Dakhill, SR; Flynn, PJ; Giannini, C; Jaeckle, KA; James, CD; Krauss, JC; Schaefer, PL; Scheithauer, BW; Uhm, JH; Wu, W | 1 |
| Catot, S; Colomer, R; de Castro, J; Guillem, V; Gúrpide, A; Isla, D; Lianes, P; Massutí, B; Mayo, C; Paz-Ares, L; Polo, E; Porta, R; Pradas, A; Puig, T; Queralt, C; Reguart, N; Rosell, R; Salinas, P; Sánchez-Torres, JM; Tarón, M | 1 |
| Cloughesy, TF; Gilbert, MR; Klencke, B; Nghiemphu, P; Prados, MD; Reardon, DA; Vredenburgh, JJ; Yung, WK | 1 |
| Blackhall, FH; Kennedy, SJ; Milenkova, T; Nicolson, M; O'brien, M; Schmid, P; Taylor, P; Thatcher, N | 1 |
| Stupp, R; Tabatabai, G | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Hamilton, M; Herndon, JE; Marcello, J; Mathe, A; McLendon, RE; Norfleet, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Cognetti, F; Crinò, L; Fabi, A; Foglietta, J; Giannarelli, D; Gori, S; Metro, G; Mottolese, M; Papaldo, P; Russillo, M; Stocchi, L; Vidiri, A | 1 |
| Becker, A; Postmus, PE; Smit, EF; van Wijk, A | 1 |
| Antti, H; Bergenheim, AT; Henriksson, R; Johansson, M; Sandström, M; Wibom, C | 1 |
| Kelly, K; Linnoila, RI; Munasinghe, J; Yin, JJ; Zhang, L | 1 |
| Chen, C; Damek, D; Fields, EC; Gaspar, LE; Kavanagh, BD; Lillehei, K; Liu, AK; Waziri, A | 1 |
| Fine, HA; Floeter, MK; Iwamoto, FM; Kreisl, TN; Lehky, TJ | 1 |
| Barlesi, F; Tomasini, P | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N | 1 |
| Katano, M; Morisaki, T; Nakafusa, Y; Nakashima, Y; Onishi, H; Yokohata, K | 1 |
| Claes, A; Hamans, BC; Heerschap, A; Jeuken, JW; Leenders, WP; Navis, AC; Wesseling, P | 1 |
| Addeo, R; Caraglia, M | 1 |
| Bota, DA; Gong, X; Linskey, ME; Schwartz, PH | 1 |
| Asano, K; Ohkuma, H | 1 |
| Callahan, R; Hurvitz, S | 1 |
| Batchelor, TT; Bjornerud, A; Borra, RJ; Emblem, KE; Jain, RK; Mouridsen, K; Sorensen, AG | 1 |
| Andronesi, OC; Batchelor, TT; Catana, C; Jain, RK; Jennings, DL; Kim, H; Ratai, EM; Sorensen, AG | 1 |
| Andersen, B; Dicker, AP; Lawrence, RY; Liu, Y; Wachsberger, PR; Xia, X | 1 |
| Cui, CX; Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, HY; Wang, Y; Zhang, XR; Zhao, LD | 1 |
| Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sophie, S; Zanetti, A | 1 |
| Halatsch, ME; Karpel-Massler, G; Wirtz, CR | 1 |
| Katzumata, A; Kawauchi, M; Kuramoto, S; Matsumoto, Y; Ono, Y; Toyoshima, A; Toyota, Y | 1 |
| Chatelut, E; Civade, E; Delord, JP; Geoerger, B; Hennebelle, I; Le Deley, MC; Thomas, F; Vassal, G; White-Koning, M | 1 |
| Chen, YY; Kiura, K; Noujima, D; Ochi, N; Takigawa, N; Tanimoto, M; Tanimoto, Y; Zhang, D | 1 |
| Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D | 1 |
| Halatsch, ME; Karpel-Massler, G; Kast, RE; Westhoff, MA; Wirtz, CR | 1 |
| Chida, K; Inui, N; Matsuura, S; Nakamura, Y; Ozawa, Y; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Baryawno, N; Ekström, TJ; Johnsen, JI; Larsson, C; Marino, AM; Sofiadis, A; Vukojević, V | 1 |
| Kagohashi, K; Kawaguchi, M; Kurishima, K; Nakayama, H; Ohara, G; Satoh, H | 1 |
| Chang, CY; Chen, CJ; Shen, CC; Su, HL | 1 |
| Kim, C; Lee, KB; Shah, BP; Subramaniam, P | 1 |
| Bai, F; Broniscer, A; Johnson, J; Stewart, CF; Wang, F; Yang, L | 1 |
| Erasmus, JJ; Stewart, DJ | 1 |
| Keiding, S; Meldgaard, P; Memon, A; Nexo, E; Sorensen, BS; Sorensen, L; Weber, B; Winterdahl, M | 1 |
| Acquaviva, J; Boskovitz, A; Bronson, RT; Charest, A; Donovan, M; Housman, DE; Jun, HJ; Lessard, J; Pfannl, R; Raval, A; Ruiz, R; Whittaker, CA; Woolfenden, S; Zhu, H | 1 |
| Lanuti, M; Mino-Kenudson, M; Sequist, LV; Sharma, A | 1 |
| Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA | 1 |
| Chao, YS; Cherniack, AD; Chiang, D; Cho, J; Dutt, A; Johnson, W; Kesari, S; Kwon, J; Meyerson, M; Onofrio, RC; Pastorino, S; Vandenberg, S; Verhaak, R; Watanabe, H; Xu, X; Yuza, Y; Zeng, Q | 1 |
| Castellino, S; Gril, B; Hua, E; Lockman, J; Lockman, PR; Mittapalli, RK; Palmieri, D; Polli, JW; Rubin, SD; Rudraraju, V; Samala, R; Smith, QR; Steeg, PS; Taskar, KS; Thorsheim, HR | 1 |
| Cheng, Y; Huber-Keener, KJ; Keihack, H; Liao, J; Liu, X; Ren, X; Rubin, E; Yan, L; Yang, JM; Zhang, L; Zhang, Y; Zhou, L | 1 |
| Akhavan, D; Amzajerdi, AN; Babic, I; Chakravarti, A; Cloughesy, TF; Dang, J; Deangelis, LM; Dejesus, J; Gini, B; Guo, D; Hong, C; Huang, TT; Iwanami, A; James, CD; Kuga, D; Lisiero, DD; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nathanson, D; Prados, MD; Prins, RM; Reinitz, F; Robins, HI; Soto, H; Tanaka, K; Tontonoz, P; Wen, PY; Youssef, M; Zhu, S | 1 |
| Anchisi, S; Bernhard, J; Bodis, S; Caspar, CB; Cathomas, R; D'Addario, G; Fischer, N; Klingbiel, D; Kotrubczik, NM; Mayer, M; Pesce, GA; Peters, S; Pilop, C; Pless, M; Ribi, K; Schlaeppi, M; Stupp, R; von Moos, R; Weber, DC; Zouhair, A | 1 |
| Düwel, P; Gehl, HB; Görner, M; Hirnle, P; Müller, F; Riesenberg, H | 1 |
| Ancukiewicz, M; Batchelor, TT; Emblem, KE; Ivy, P; Jain, RK; Jennings, D; Kim, H; Polaskova, P; Sorensen, AG; Wang, M; Wen, PY | 1 |
| Borges, KS; Brassesco, MS; Carlotti, CG; Castro-Gamero, AM; da Silva Silveira, V; de Oliveira, HF; de Paula Queiroz, RG; Moreno, DA; Scrideli, CA; Tone, LG | 1 |
| Chen, J; Fan, Y; Li, Q; Xing, X; Yu, Q; Zhan, H; Zhan, L; Zhang, Y | 1 |
| Lee, SH | 1 |
| Amberger-Murphy, V; Clarke, C; Clynes, M; Doolan, P; Farrell, M; Howley, R; Kinsella, P; Madden, SF | 1 |
| Azim, HA | 1 |
| Bai, H; Han, B | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; McLendon, RE; McSherry, F; Peters, KB; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Threatt, S; Vredenburgh, JJ; Zhang, S | 1 |
| Constantini, S; Kane, R; MacDonald, TJ; McCowage, G; Packer, RJ; Rood, B; Yalon, M | 1 |
| Fu, H; Hu, YD; Liu, XJ; Long, C; Xiao, Y; Zhang, XL | 1 |
| Gao, Q; Kang, KB; Ty, A; Wong, MC; Wong, YL; Zhu, C | 1 |
| Baldotto, CS; da Silveira, JS; de Lima Araújo, LH; Ferreira, CG; Zukin, M | 1 |
| Lemmon, MA; Park, JH | 1 |
| Barkovich, KJ; Blair, JA; Fan, QW; Garske, AL; Hariono, S; Nicolaides, T; Shokat, KM; Weiss, WA; Zhang, J | 1 |
| Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S | 1 |
| Guo, Z; Li, J | 1 |
| Chen, LK; Dinglin, XX; Liang, Y; Liao, H; Liu, JL; Xu, F; Zeng, YD; Zhang, L | 1 |
| Kim, HT; Kim, KP; Kim, SW; Lee, DH; Lee, JS; Park, SJ; Suh, C | 1 |
| Kato, Y; Kawamura, H; Makino, T; Nishina, M; Yokoyama, E | 1 |
| Alici, S; Arslan, UY; Bilici, M; Boruban, C; Buyukberber, S; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Mert, AG; Ozkan, M; Suner, A; Tarhan, MO; Unal, OU; Urakci, Z; Yaman, S; Yildiz, R | 1 |
| Rudà, R; Soffietti, R; Trevisan, E | 1 |
| Chung, JS; Im, YH; Kim, S; Kim, TY; Moon, H; Park, S; Rha, SY; Ro, J; Santillana, S | 1 |
| Chen, M; Hu, P; Li, L; Nie, L; Wang, M; Xiao, Y; Zhang, L; Zhao, J; Zhong, W | 1 |
| Lim, E; Lin, NU | 1 |
| Bachoo, RM; Cavenee, WK; Dang, J; DePinho, RA; Fenton, TR; Furnari, FB; Inda, MM; Iwanami, A; James, CD; Kuga, D; Marie, SK; Mischel, PS; Nathanson, D; Oba-Shinjo, SM; Ponte de Albuquerque, C; Tanaka, K; Uno, M; Vandenberg, SR; Wykosky, J; Yang, H; Zhou, H | 1 |
| Cornelio, GH; Devi, BC; Khorprasert, C; Kim, SB; Kim, TY; Kobayashi, M; Landis, SH; Lee, SC; Moon, H; Park, YH; Ro, J; Sohn, JH; Sutandyo, N; Wong, DW; Yap, YS; Yeoh, EM | 1 |
| Cloughesy, T; Green, RM; Lai, A; Nghiemphu, PL; Reardon, DA | 1 |
| Fujii, N; Fujimoto, N; Kato, T; Nagao, T; Nakanishi, G; Tanaka, T; Toda, N | 1 |
| Aiken, RD; Akerley, WA; Beelen, AP; Colman, H; De Groot, JF; Evans, BA; Glantz, M; Grossmann, KF; Jensen, RL; Matsuoko, Y; Olsen, JJ; Olson, JJ; Yu, M | 1 |
| Boockvar, JA; Christos, P; Kaplan, R; Kesavabhotla, K; Lavi, E; Mubita, L; Pannullo, SC; Scheff, R; Schlaff, CD; Shin, B; Tsiouris, AJ | 1 |
| Jain, A; Ryan, PD; Seiden, MV | 1 |
| Antoine, M; Blons, H; Buisine, MP; Cadranel, J; Chetaille, B; Chouaid, C; Coudert, B; Daniel, C; Danton, G; De Fraipont, F; Faller, M; Foucher, P; Lacroix, L; Longchampt, E; Mauguen, A; Michiels, S; Morin, F; Pignon, JP; Poulot, V; Quoix, E; Solassol, J; Urban, T; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Booth, L; Chen, CS; Cruickshanks, N; Dent, P; Grant, S; Ridder, T | 1 |
| Fujiwara, Y; Ito, Y; Iwata, H; Katsura, K; Narabayashi, M; Saji, S; Sasaki, Y; Usami, S | 1 |
| de Groot, J; Fuller, G; Heimberger, AB; Kong, LY; Liang, J; Piao, Y; Qiao, W; Wei, J | 1 |
| Chohnabayashi, N; Inoue, A; Mochizuki, S; Murakami, K; Nishimura, N; Nukiwa, T | 1 |
| Gallia, GL; Joshi, AD; Loilome, W; Riggins, GJ; Siu, IM; Tyler, B | 1 |
| Bianchi, L; Lisi, P; Minotti, V; Stingeni, L | 1 |
| Ager, E; Chung, E; Duyverman, AM; Eichler, AF; Engelman, JA; Farrar, CT; Fukumura, D; Goel, S; Hiddingh, L; Huang, Y; Incio, J; Jain, RK; Kamoun, W; Kodack, DP; Lussiez, A; Mahmood, S; Snuderl, M; Song, Y; Tannous, BA; Yamashita, H | 1 |
| Fine, HA; Iwamoto, FM; Kreisl, TN; McNeill, KA; Shih, J; Sul, J | 1 |
| Airiau, K; Avril, T; Belaud-Rotureau, MA; Belloc, F; Dugay, F; Eimer, S; Quillien, V | 1 |
| Cui, K; Hao, A; Jin, G; Liu, Q; Nie, F; Wang, L; Wong, ST; Yao, L; Zhao, H | 1 |
| Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G | 1 |
| Bartsch, R; Preusser, M | 1 |
| Chen, GY; Cheng, Y; Huang, C; Huang, YS; Liu, Y; Lu, S; Ren, S; Wu, YL; Yan, HH; Yang, JJ; Zhou, C | 1 |
| Bianchi, F; Cenci, T; D'Alessandris, QG; Fernandez, E; Larocca, LM; Lauretti, L; Maira, G; Martini, M; Montano, N; Pallini, R | 1 |
| Fang, X; Hu, Y; Li, M; Ma, S; Shen, H; Tan, C; Yuan, Y | 1 |
| Fujita, Y; Goto, M; Hamaoka, A; Imai, A; Mizuta, N; Morita, M; Nakatsukasa, K; Sakaguchi, K; Shouji, M; Taguchi, T; Umeda, Y | 1 |
| Aisner, DL; Bunn, PA; Burke, JM; Camidge, DR; Doebele, RC; Gan, G; Gaspar, LE; Kavanagh, BD; Lu, X; Scheier, B; Weickhardt, AJ | 1 |
| Brachman, DG; Bredel, M; Chakravarti, A; Choucair, A; Christiansen, J; Curran, WJ; Dicker, AP; Dolled-Filhart, M; Gustavson, M; Lautenschlaeger, T; Mehta, M; Mischel, P; Molinaro, A; Robins, HI; Schultz, CJ; Wang, M | 1 |
| Andreu, X; Baena, C; Bronchud, MH; Castillo, S; Escriva de Romaní, S; Esquius, J; Fernández, A; Julia, JC; Mourelo, S; Murillo, J; Romero, R | 1 |
| Akerley, W; Boucher, K; Bylund, J; Egbert, L; Harker, G; Reddy, C; Rich, N; Van Duren, T | 1 |
| D'Alessandris, QG; Pallini, R | 1 |
| Nieder, C | 2 |
| Basavalingaiah, A; Madhusudhan, N; Revannasiddaiah, S; Susheela, SP | 1 |
| Bachelot, T; Campone, M; Cropet, C; Diéras, V; Jimenez, M | 1 |
| Higami, Y; Kato, M; Kobayashi, T; Koshimo, Y; Marumo, S; Takeda, M; Teranishi, T | 1 |
| Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D | 1 |
| Cho, N; Hayashi, M; Yomo, S | 1 |
| Bachelot, T; Bonneterre, J; Gilabert, M; Gonçalves, A; Heudel, P; Labidi-Gally, I; Le Rhun, E; Pierga, JY | 1 |
| Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X | 1 |
| Akman, T; Alici, S; Arslan, UY; Boruban, C; Coskun, U; Dayan, A; Demir, L; Durnalı, AG; Elkiran, ET; Geredeli, C; Gumusay, O; Inal, A; Inanc, M; Isikdogan, A; Kaplan, MA; Koca, D; Kocer, M; Kucukoner, M; Oksuzoglu, B; Ozdemir, NY; Sener, N; Suner, A; Tarhan, MO; Urakci, Z; Yildiz, R | 1 |
| Allen, PK; Amini, A; Brown, P; Chang, JY; Chen, SS; Garland, LL; Heymach, JV; Holt, J; Kim, ES; Komaki, R; Liao, Z; McGovern, SL; Munsell, MF; Stea, B; Sulman, E; Unger, W; Wefel, JS; Welsh, JW | 1 |
| Albanese, C; Alzani, R; Amboldi, N; Brasca, M; Ciomei, M; Degrassi, A; Festuccia, C; Fiorentini, F; Galvani, A; Gravina, G; Mercurio, C; Pastori, W; Pesenti, E | 1 |
| Kapoor, S | 1 |
| Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY | 1 |
| Besse, B; Chaubet-Houdu, M | 1 |
| Buyyounouski, MK; Demas, W; Khuntia, D; Komaki, R; Mehta, MP; Nedzi, LA; Perry, G; Robins, HI; Schell, MC; Shah, SA; Souhami, L; Sperduto, PW; Suh, JH; Wang, M; Werner-Wasik, M | 1 |
| Archer, GE; Bigner, DD; Chewning, TA; Friedman, AH; Friedman, HS; Heimberger, AB; Learn, CA; McLendon, RE; Pracyk, JB; Sampson, JH; Tuck, FL | 1 |
| Mauer, AM; Villano, JL; Vokes, EE | 1 |
| Bartolini, S; Calandri, C; Cappuzzo, F; Crinò, L | 1 |
| Ardizzoni, A; Bartolini, S; Calandri, C; Cappuzzo, F; Crinò, L; Gridelli, C; Maione, P; Santoro, A; Soto-Parra, H; Tiseo, M | 1 |
| Ahmed Rasheed, BK; Bigner, DD; Dancey, JE; Dowell, JM; Friedman, AH; Friedman, HS; Herndon, JE; Kao, JC; McLendon, RE; Peery, T; Penne, KL; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Stenzel, TT; Tourt-Uhlig, SE; Van Duyn, LB; Vredenburgh, JJ; Wikstrand, CJ | 1 |
| Ambrad, AA; Carey, S; Falsey, R; Glanzberg, H; Kislin, K; Martinez, JD; Meuillet, EJ; Patel, J; Stea, B | 1 |
| Hochberg, FH; Kirsch, DG | 1 |
| Katz, A; Zalewski, P | 1 |
| Fan, QW; Goldenberg, DD; Shokat, KM; Specht, KM; Weiss, WA; Zhang, C | 1 |
| Ebihara, S; Ohrui, T; Sasaki, H; Takahashi, H; Yamada, M | 1 |
| Bartolini, S; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Villa, E | 1 |
| Aderka, D; Levitt, ML; Pfeffer, MR | 1 |
| Andersson, U; Bergenheim, AT; Bergh, A; Henriksson, R; Johansson, M; Sandström, M | 1 |
| Amano, H; Hoshi, S; Kono, C; Yamada, Y; Yamaguchi, T | 1 |
| Eisenmann, C; Klumpp, A; Steinbach, JP; Weller, M | 1 |
| Rasheed, BK; Rich, JN; Yan, H | 1 |
| de Waal, R; Heerschap, A; Küsters, B; Leenders, WP; Maass, C; Ruiter, D; Ryan, A; Verrijp, K; Wesseling, P | 1 |
| Ishida, A; Iwamoto, Y; Kanoh, K; Kohno, N; Miyazawa, T; Miyazu, Y; Nishisaka, T | 1 |
| Fujiwara, K; Hisamoto, A; Hotta, K; Kiura, K; Kozuki, T; Okada, T; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Ito, M; Iwasaki, T; Kawamura, S; Kijima, T; Kimura, H; Maeda, H; Nakagawa, M; Namba, Y; Niinaka, M; Okada, T; Okumura, Y; Takeda, Y; Yamaguchi, T; Yokota, S | 1 |
| Ho, SS; Mok, TS; Poon, AN; Yeo, W | 1 |
| Chen, YM; Chiang, SC; Chiu, CH; Liou, JL; Perng, RP; Tsai, CM | 1 |
| Carpentier, AF | 1 |
| Barber, TD; Kinzler, KW; Velculescu, VE; Vogelstein, B | 1 |
| Carminati, O; De Giorgi, U; Kopf, B; Marangolo, M; Rosti, G; Zago, S | 1 |
| Antonella, P; Augusto, P; Busi, G; Giancarla, B; Palumbo, A; Pedrazzini, A; Roggero, E | 1 |
| Han, JY; Hong, EK; Kim, HK; Kim, HY; Lee, DH; Lee, EK; Lee, HG; Lee, JJ; Lee, JS | 1 |
| Abrey, LE; Franceschi, E; Kris, MG; Miller, VA; Milton, DT; Omuro, AM; Shah, N | 1 |
| Carpentier, AF; Delattre, JY; Hoang-Xuan, K; Marie, Y; Omuro, AM; Sanson, M; Thillet, J | 1 |
| Hiddemann, W; Krych, M; Ostermann, H; Schoenberg, SO; Stemmler, HJ; Weigert, O | 1 |
| Raizer, JJ | 1 |
| Kurisu, K; Okamura, T | 1 |
| Abrey, LE; Chang, S; Cowell, JK; DeAngelis, LM; Gilbert, MR; Grefe, CN; Holland, EC; Kuhn, JG; Lamborn, K; Lassman, AB; Lieberman, FS; Nowak, NJ; Pao, W; Prados, M; Raizer, JJ; Razier, JR; Rossi, MR; Shih, AH; Wen, P; Wilson, R; Yung, WA | 1 |
| Dudek, AZ; Keshtgarpour, M; Kmak, KL; Koopmeiners, J | 1 |
| Goto, H; Imao, M; Kato, T; Nakashima, M; Sano, K; Yasuda, S; Yoshimura, K | 1 |
| Boshoff, C; Falzon, M; Lai, CS; Lee, SM | 1 |
| Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D | 1 |
| Behnke-Mursch, J; Halatsch, ME; Schmidt, U; Unterberg, A; Wirtz, CR | 1 |
| Hatano, H; Ishii, D; Kosaka, T; Mitsudomi, T; Mizuno, M; Nakahara, N; Natsume, A; Shimato, S; Wakabayashi, T; Yatabe, Y; Yoshida, J | 1 |
| Frei, K; Hofer, S; Rutz, HP | 1 |
| Berger, MS; Keles, GE | 1 |
| Ballman, KV; Brown, PD; Buckner, JC; Fiveash, JB; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Krishnan, S; Nabors, LB; Uhm, JH | 1 |
| Mitra, SS; Simcock, R | 1 |
| Fujiwara, Y; Hotta, K; Kiura, K; Segawa, Y; Shinkai, T; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S | 1 |
| Frei, K; Hofer, S | 1 |
| Arimura, K; Higashimoto, I; Machida, K; Matsuyama, W; Mitsuyama, H; Osame, M; Watanabe, M; Yamamoto, M | 1 |
| Gaya, A; Khorshid, M; Plowman, PN; Walther, JC | 1 |
| Fujimoto, K; Kawai, S; Masui, K; Nishi, N; Yonezawa, T | 1 |
| Chianese, M; Cimmino, G; Laus, G; Penitente, R; Pepe, S; Prece, D; Quesada, P | 1 |
| An, TT; Fang, J; Liu, XY; Wu, MN; Yang, L | 1 |
| Hughes, S; Meehan, L; Moore, S; Norton, A; O'Brien, M; Papadopoulos, P; Popat, S; Priest, K; Wilkins, A | 1 |
| Gutin, PH; Hormigo, A; Rafii, S | 1 |
| Ancukiewicz, M; Batchelor, TT; Benner, T; Cahill, DP; Chen, PJ; Cohen, KS; di Tomaso, E; Drappatz, J; Duda, DG; Ivy, P; Jain, RK; Kozak, KR; Loeffler, JS; Louis, DN; Mrugala, MM; Plotkin, S; Scadden, DT; Sorensen, AG; Wen, PY; Zhang, WT; Zhu, M | 1 |
| Abe, T; Haraguchi, M; Hayashi, M; Ito, K; Tsutsui, N | 1 |
| Ashitani, J; Imai, K; Kodama, T; Kyoraku, Y; Matsumoto, N; Nakazato, M; Sano, A; Yanagi, S | 1 |
| Bai, F; Broniscer, A; Fraga, C; Gajjar, A; Krasin, MJ; O'Shaughnessy, M; Panetta, JC; Stewart, CF | 1 |
| de Waal, RM; Kats, G; Küsters, B; Leenders, WP; Roodink, I; Ruiter, DJ; Verrijp, K; Wesseling, P | 1 |
| Blatt, V; Brandes, AA; Cavallo, G; Crinò, L; Franceschi, E; Grosso, D; Lonardi, S; Magrini, E; Pession, A; Scopece, L; Tallini, G; Tosoni, A; Urbini, B | 1 |
| Carlson, BL; Dinca, EB; Galanis, E; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Sarkaria, JN; Schroeder, MA; Wu, W; Yang, L | 1 |
| Akie, K; Asahina, H; Dosaka-Akita, H; Harada, M; Ishida, T; Isobe, H; Kinoshita, I; Konishi, J; Munakata, M; Nishimura, M; Ogura, S; Sukoh, N; Yamazaki, K; Yokouchi, H | 1 |
| Gabizon, A; Gipps, M; Grenader, T; Shavit, L | 1 |
| Garfield, D | 1 |
| Li, YL; Li, Z; Wang, ZM; Wei, Z; Wu, C; Zhang, TX | 1 |
| Hatake, K | 1 |
| Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK | 1 |
| Baker, SD; Cusatis, G; Ghio, D; Gregorc, V; Hidalgo, M; Ingersoll, RG; Ludovini, V; Marsh, S; Sparreboom, A; Spreafico, A; Steinberg, SM; Viganò, MG; Villa, E | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Galetta, D; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Huang, MY; Huang, YJ; Liu, SF; Wang, CJ | 1 |
| Bradner, JE; Brennan, C; Chin, L; DePinho, RA; Kimmelman, AC; Ligon, KL; Nabioullin, R; Ponugoti, AH; Stegh, AH; Stommel, JM; Wiedemeyer, R; Ying, H | 1 |
| Pan, M; Santamaria, M; Wollman, DB | 1 |
| Andersson, U; Behnam-Motlagh, P; Johansson, D; Johansson, M; Malmer, B | 1 |
| Cadranel, J; Gounant, V; Khalil, A; Lavole, A; Milleron, B; Poulot, V; Wislez, M | 1 |
| Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Lillehei, K; Schwer, AL; Stuhr, K | 1 |
| Fekrazad, MH; Jones, DV; Ravindranathan, M | 1 |
| Adams, M; Borowski, V; Butler, J; Connolly, PJ; Emanuel, SL; Fuentes-Pesquera, A; Greenberger, LM; Gruninger, RH; Hollister, B; Hughes, TV; Middleton, SA; Moreno-Mazza, S; Napier, C; Pandey, N; Rugg, CA; Story, JR | 1 |
| Chen, GS; Lan, CC; Wu, CY | 1 |
| Claes, A; Gambarota, G; Hamans, B; Heerschap, A; Leenders, W; Maass, C; van Tellingen, O; Wesseling, P | 1 |
| Claes, A; Heerschap, A; Jeuken, J; Leenders, WP; Maass, C; Wesseling, P | 1 |
| Dasmahapatra, B; Demma, MJ; Naumann, U; Roth, P; Weinmann, L; Weller, M; Wischhusen, J | 1 |
| Chen, L; Zhang, PL | 1 |
| Bergenheim, AT; Bergström, P; Henriksson, R; Johansson, M; Sandström, M | 1 |
| Costa, DB; Kobayashi, S | 1 |
| Aoki, H; Ikegame, Y; Inagaki, A; Iwama, T; Kunisada, T; Nakashima, S; Oka, N; Soeda, A; Yoshimura, S | 1 |
| Duell, T; Poellinger, B; von Pawel, J; Wagner, H | 1 |
| Devanz, P; Gaspar, N; Geoerger, B; Grill, J; Lacroix, L; Lecluse, Y; Morizet, J; Opolon, P; Valent, A; Vassal, G | 1 |
| Bullitt, E; Burstein, HJ; Carey, LA; Come, SE; Crawford, A; Ewend, M; Gelman, R; Harris, GJ; Henson, JW; Hochberg, F; Kasparian, E; Kirsch, DG; Li, X; Lin, NU; Liu, MC; Van den Abbeele, AD; Winer, EP; Younger, J | 1 |
| Bertalanffy, A; Dieckmann, K; Dietrich, W; Gelpi, E; Hainfellner, JA; Marosi, C; Prayer, D; Preusser, M; Rottenfusser, A; Widhalm, G | 1 |
| Liau, LM; Salgaller, ML | 1 |
| Li, AW; Xu, JF; Zhou, CC | 1 |
| Li, LY; Wang, HZ; Wang, MZ; Wang, SL; Wu, C; Zhang, L; Zhang, XT; Zhong, W | 1 |
| Baccanari, DP; Boytos, CM; Caddell, JM; Comley, JC; Friedman, HS; Hunter, RN; Jones, ML; Joyner, SS; Knick, V; Kuyper, LF; Rudolph, SK; Stables, JN; Tansik, RL; Wilson, HR | 1 |
| Liu, XP; Myers, DE; Narla, RK; Uckun, FM | 1 |
| Burgess, AW; Cavenee, WK; Huang, HJ; Levitzki, A; Mishima, K; Nagane, M; Narita, Y | 1 |
| Cavenee, WK; Huang, HJ; Steinbach, JP; Supra, P; Weller, M | 1 |
| Giese, NA; Hollenbach, SJ; Israel, MA; Lokker, NA; Sullivan, CM | 1 |
58 review(s) available for quinazolines and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2021 |
HER2-positive metastatic breast cancer: a comprehensive review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Female; Humans; Immunoconjugates; Neoplasm Metastasis; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2021 |
Current treatment options for HER2-positive breast cancer patients with brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Humans; Oxazoles; Pyridines; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2021 |
The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
Topics: Afatinib; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Receptor, ErbB-2 | 2018 |
A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Cell Hypoxia; Clinical Trials as Topic; Disease Progression; Drug Antagonism; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Biological; Myeloid Cells; Neoplasm Proteins; Neovascularization, Pathologic; Patient Selection; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Tumor Microenvironment; Vascular Endothelial Growth Factors | 2013 |
The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Brain Neoplasms; Chemoradiotherapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Standards of care and novel approaches in the management of glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Cancer Vaccines; Electric Stimulation Therapy; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Immunotherapy; Quinazolines; Snake Venoms; Standard of Care; Vaccines, Subunit | 2014 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Neoplasms; Molecular Targeted Therapy; Prognosis; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
Erlotinib: early clinical development in brain cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2014 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2014 |
Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Disease Management; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neural Stem Cells; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2015 |
Critical role of ABCG2 in ALA-photodynamic diagnosis and therapy of human brain tumor.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Brain Neoplasms; Gefitinib; Humans; Mice; Neoplasm Proteins; NF-E2-Related Factor 2; Oxidative Stress; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Protoporphyrins; Quinazolines; Transcription, Genetic; Treatment Outcome | 2015 |
[Systemic treatment of brain metastases from breast cancer].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Genes, erbB-2; Humans; Lapatinib; Medicine; Molecular Targeted Therapy; Patient Care Team; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
HER2-positive metastatic breast cancer: a changing scenario.
Topics: Ado-Trastuzumab Emtansine; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Maytansine; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2015 |
Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
[Radiotherapy concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2015 |
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
Topics: Antibodies, Monoclonal, Humanized; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Delivery Systems; Female; Humans; Immunoconjugates; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines | 2016 |
Rapid onset of radiation maculopathy after whole-brain radiation therapy: A case report.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Dose-Response Relationship, Radiation; Female; Gefitinib; Humans; Lung Neoplasms; Macular Degeneration; Middle Aged; Quinazolines; Radiation Injuries; Visual Acuity | 2016 |
New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2009 |
[Advances in research on treatment of breast cancer with lapatinib].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Proliferation; ErbB Receptors; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2008 |
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.
Topics: Brain Edema; Brain Neoplasms; Humans; Magnetic Resonance Imaging; Neovascularization, Pathologic; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Quinazolines; Temozolomide | 2009 |
Treatment of brain metastases in patients with HER2+ breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Incidence; Lapatinib; Prognosis; Quinazolines; Receptor, ErbB-2; Time Factors; Trastuzumab | 2009 |
Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2010 |
[Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Trastuzumab; Treatment Outcome | 2009 |
Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gefitinib; Hemorrhage; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Quinazolines; Tomography, X-Ray Computed | 2010 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2010 |
Systemic treatment in breast-cancer patients with brain metastasis.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; Biological Products; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lapatinib; Quinazolines | 2010 |
[Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Glioma; Humans; Microcirculation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Snake Venoms; Vascular Endothelial Growth Factor A | 2010 |
Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.
Topics: Angiogenesis Modulating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
[Her2 positive breast cancer: practices].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Genes, erbB-2; Heart; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug Combinations; Drug Synergism; Erlotinib Hydrochloride; Glioma; Humans; Models, Biological; Neoplasm Grading; Quinazolines | 2011 |
Erlotinib in glioblastoma: lost in translation?
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2011 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines | 2011 |
Role of chemotherapy on brain metastasis.
Topics: Brain Neoplasms; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2012 |
Targeted therapy in brain metastasis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Humans; Ipilimumab; Lapatinib; Molecular Targeted Therapy; Neovascularization, Pathologic; Quinazolines | 2012 |
New insights and emerging therapies for breast cancer brain metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Paclitaxel; Peptides; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy; Receptor, ErbB-2; Trastuzumab | 2012 |
Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: case report and review of the literature of alopecia associated with EGFR inhibitors.
Topics: Aged; Alopecia; Antineoplastic Agents; Asian People; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Scalp Dermatoses | 2012 |
EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
[Brain metastases of non small cell lung cancers: systemic treatments].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines | 2013 |
Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quality of Life; Quinazolines | 2003 |
Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Brain metastasis responding to gefitinib alone.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gingival Neoplasms; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2004 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Resistance, Neoplasm; Gefitinib; Glioblastoma; Glioma; Humans; Meta-Analysis as Topic; Nitrosourea Compounds; Oligodendroglioma; Paraneoplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Temozolomide | 2005 |
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2005 |
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2006 |
Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Humans; Magnetic Resonance Imaging; Neovascularization, Pathologic; Quinazolines | 2007 |
[Breast cancer and Her-2].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; ErbB Receptors; Female; Gene Targeting; Humans; Lapatinib; Protease Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2007 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
114 trial(s) available for quinazolines and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxazoles; Placebos; Prospective Studies; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2021 |
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2022 |
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Topics: Adenocarcinoma of Lung; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Consolidation Chemotherapy; Diarrhea; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Oxazoles; Progression-Free Survival; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2020 |
A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Vinorelbine | 2019 |
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2020 |
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Double-Blind Method; Female; Humans; Middle Aged; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult | 2020 |
Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiosurgery | 2017 |
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Karnofsky Performance Status; Lapatinib; Male; Middle Aged; Necrosis; Pilot Projects; Quinazolines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2017 |
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2017 |
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2017 |
Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Quinazolines; Reproducibility of Results; Retrospective Studies; Statistics, Nonparametric; Time Factors; Treatment Outcome | 2017 |
Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal, Humanized; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Calcium-Binding Proteins; Cohort Studies; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; ErbB Receptors; Female; Glioblastoma; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Microfilament Proteins; Necrosis; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Ribosomal Protein S6; Signal Transduction; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2018 |
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; International Agencies; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate | 2013 |
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Dacarbazine; Disease-Free Survival; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome | 2013 |
Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Brain Neoplasms; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2013 |
Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Trastuzumab; Treatment Outcome | 2013 |
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Enzyme-Linked Immunosorbent Assay; Glioblastoma; Humans; Magnetic Resonance Imaging; Oxygen; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Statistics, Nonparametric; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Survival Rate; Tissue Distribution; Young Adult | 2014 |
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Treatment Outcome; Young Adult | 2014 |
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cranial Irradiation; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recovery of Function; Treatment Outcome | 2014 |
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Temozolomide; Treatment Outcome | 2015 |
All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2014 |
Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Gefitinib; Humans; Male; Melphalan; Middle Aged; Prednisolone; Quinazolines; Radiotherapy, Intensity-Modulated; Treatment Outcome; Vindesine | 2015 |
Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis | 2014 |
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Sirolimus | 2015 |
Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Polyethylene Glycols; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Snake Venoms; Treatment Outcome; Young Adult | 2015 |
A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines | 2015 |
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 tr
Topics: Adult; Afatinib; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Canada; Disease Progression; Disease-Free Survival; Europe; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Republic of Korea; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2015 |
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Treatment Outcome | 2016 |
A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Quinazolines | 2016 |
Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Crown Ethers; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2016 |
Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Brain; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Tissue Distribution; Treatment Outcome | 2017 |
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Piperidines; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy | 2016 |
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2016 |
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2008 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Quinazolines; Rhabdomyosarcoma; Temozolomide | 2008 |
Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Radiosurgery; Tumor Burden; Young Adult | 2009 |
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; ErbB Receptors; Everolimus; Female; Gefitinib; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Sirolimus | 2009 |
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Gliosarcoma; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Temozolomide | 2009 |
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines | 2009 |
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Topics: Adolescent; Adult; Anticonvulsants; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Temozolomide | 2009 |
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2009 |
Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2009 |
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain Neoplasms; Cytochrome P-450 CYP3A; Enzyme Induction; ErbB Receptors; Female; Glioblastoma; Humans; Lapatinib; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2 | 2010 |
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quinazolines | 2009 |
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Quinazolines; Receptor, ErbB-2; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2010 |
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Diverticulitis; Drug Administration Schedule; ErbB Receptors; Female; Gastrointestinal Hemorrhage; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Piperidines; Quinazolines; Temozolomide; Thrombocytopenia; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult | 2010 |
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tissue Distribution | 2010 |
[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Smoking; Survival Rate | 2010 |
Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib.
Topics: Antineoplastic Agents; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Glioblastoma; Humans; Image Interpretation, Computer-Assisted; Proportional Hazards Models; Quinazolines | 2010 |
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Young Adult | 2010 |
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Dexamethasone; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Enzyme Activators; ErbB Receptors; Female; Gefitinib; Gene Amplification; Genes, erbB-1; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Quinazolines; Young Adult | 2011 |
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2010 |
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperidines; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate; Tissue Distribution | 2010 |
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carboplatin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Dexamethasone; Drug Administration Schedule; Female; Glioma; Glucocorticoids; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide; Tumor Burden; Vincristine; Young Adult | 2012 |
T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients.
Topics: Angiogenesis Inhibitors; Brain Neoplasms; Contrast Media; Disease-Free Survival; Female; Glioblastoma; Humans; Magnetic Resonance Angiography; Male; Quinazolines; Radiography; Survival Rate | 2011 |
Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Female; Glioblastoma; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult | 2011 |
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Squamous Cell; Child; Child, Preschool; Cytochrome P-450 CYP3A; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Young Adult | 2011 |
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan | 2011 |
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cognition; Cranial Irradiation; Dacarbazine; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Quality of Life; Quinazolines; Survival Analysis; Temozolomide | 2012 |
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
Topics: Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Disease-Free Survival; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2012 |
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Quinazolines; Thiazoles; Tissue Distribution; Young Adult | 2012 |
A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Quinazolines; Sequence Deletion; Treatment Outcome | 2012 |
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2012 |
A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Sirolimus; Survival Rate; Tissue Distribution | 2012 |
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Cohort Studies; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate; Tissue Distribution | 2012 |
Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.
Topics: Adult; Aged; Anticonvulsants; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Recurrence | 2012 |
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; Drug Administration Schedule; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Young Adult | 2012 |
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Central Nervous System; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2 | 2013 |
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Quinazolines | 2013 |
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A | 2013 |
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.
Topics: Age Factors; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy Dosage | 2013 |
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Proteins; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proteomics; Quinazolines; Survival Analysis | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Quinazolines; Temozolomide | 2013 |
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution | 2013 |
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Socie
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome | 2014 |
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides | 2013 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide | 2013 |
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Phase II trial of gefitinib in recurrent glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2004 |
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Skin Diseases; Survival Analysis; Treatment Outcome | 2004 |
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Sex Factors | 2004 |
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2005 |
Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Skin Diseases; Smoking; Survival Analysis; Treatment Outcome | 2005 |
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Clinical Trials as Topic; Cluster Analysis; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Genome; Glioma; Humans; Lung Neoplasms; Models, Biological; Mutation; Nucleic Acid Hybridization; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Time Factors | 2005 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Temozolomide; Treatment Outcome | 2006 |
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy Dosage | 2006 |
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Topics: Brain Edema; Brain Neoplasms; Chemokine CXCL12; Chemokines, CXC; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth Factors; Flow Cytometry; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Analysis | 2007 |
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.
Topics: Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Child; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Quinazolines | 2007 |
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligodendroglioma; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quality of Life; Quinazolines; Survival Analysis | 2007 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Edema; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Gefitinib; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Quinazolines; Temozolomide | 2008 |
A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dose Fractionation, Radiation; Female; Gefitinib; Glioma; Humans; Male; Maximum Tolerated Dose; Mental Status Schedule; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Radiosurgery; Treatment Outcome | 2008 |
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2008 |
Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.
Topics: Adult; Aged; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention | 2008 |
[Gefitinib in the treatment of refractory non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Survival Rate | 2007 |
[Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Survival Rate | 2007 |
307 other study(ies) available for quinazolines and Benign Neoplasms, Brain
| Article | Year |
|---|---|
AZD3759 inhibits glioma through the blockade of the epidermal growth factor receptor and Janus kinase pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Janus Kinases; Male; Mice; Piperazines; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Drug Carriers; Humans; Induced Pluripotent Stem Cells; Lapatinib; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2 | 2021 |
Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Glioblastoma; Growth Inhibitors; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2021 |
AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1.
Topics: Acrylamides; Aniline Compounds; Animals; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Quinazolines; Xenograft Model Antitumor Assays | 2022 |
Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer.
Topics: Animals; Antineoplastic Agents, Immunological; Brain Neoplasms; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms, Experimental; Neural Stem Cells; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2022 |
Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases.
Topics: Blood-Brain Barrier; Brain Neoplasms; Catalytic Domain; DNA-Activated Protein Kinase; Humans; Pyridazines; Quinazolines; Radiation-Sensitizing Agents | 2022 |
Clinical Profile and Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Brain Metastases: Real-World Experience.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2022 |
Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study.
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2023 |
Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Trastuzumab | 2023 |
Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Immunoconjugates; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2023 |
Synergistic effect of STAT3‑targeted small interfering RNA and AZD0530 against glioblastoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Glioblastoma; Mice, Inbred BALB C; Mice, Nude; Quinazolines; RNA, Small Interfering; RNAi Therapeutics; STAT3 Transcription Factor | 2019 |
Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glioblastoma; Humans; Mice; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2019 |
Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Cranial Irradiation; Crown Ethers; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Quality of Life; Quinazolines | 2021 |
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gene Rearrangement; Genome, Human; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Republic of Korea; Treatment Outcome | 2020 |
Repeated courses of radiation treatment in an HER2-positive breast cancer patient with diffuse brain metastases: A case report.
Topics: Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2020 |
Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study.
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Survival Analysis | 2020 |
Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
Topics: Animals; Antineoplastic Agents; Azepines; Benzamides; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Glioblastoma; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; Protein Kinase Inhibitors; Quinazolines; Receptor, trkB; Tyrphostins; Xenograft Model Antitumor Assays | 2020 |
Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Injections, Intraventricular; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Quinazolines; Receptor, Notch1; Signal Transduction; SOXB1 Transcription Factors; src-Family Kinases; Stereotaxic Techniques; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mutation; Poly (ADP-Ribose) Polymerase-1; PTEN Phosphohydrolase; Quinazolines; Temozolomide; Tumor Suppressor Proteins | 2020 |
New anti-HER2 agents for brain metastasis: histology-agnostic weapons?
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2021 |
BCL6 promotes glioma and serves as a therapeutic target.
Topics: Animals; Axl Receptor Tyrosine Kinase; Brain Neoplasms; Cell Line, Tumor; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; MAP Kinase Kinase Kinases; Mice, Mutant Strains; Molecular Targeted Therapy; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Quality of Life; Quinazolines | 2017 |
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Hepatitis C, Chronic; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Smoking; Taiwan | 2017 |
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged, 80 and over; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Nude; Pemetrexed; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Random Allocation; Triazines; Xenograft Model Antitumor Assays | 2017 |
Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Computational Biology; Drug Administration Schedule; ErbB Receptors; Glioblastoma; Humans; Lapatinib; Logistic Models; Maximum Tolerated Dose; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines | 2018 |
Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Monitoring; Female; Humans; Lapatinib; Mass Spectrometry; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.
Topics: Animals; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; DNA Repair; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mutation; Piperazines; Quinazolines; Radiation-Sensitizing Agents; Xenograft Model Antitumor Assays | 2018 |
Icotinib and whole-brain radiotherapy for the treatment in patients with brain metastases from EGFR-mutant nonsmall cell lung cancer: A retrospective study.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; China; Combined Modality Therapy; Cranial Irradiation; Crown Ethers; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiotherapy Dosage; Retrospective Studies | 2018 |
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Luminescent Measurements; Lung Neoplasms; Mice; Neoplasm Staging; Piperazines; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
TLK2 enhances aggressive phenotypes of glioblastoma cells through the activation of SRC signaling pathway.
Topics: Animals; Benzodioxoles; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Knockdown Techniques; Glioblastoma; Humans; Mice; Protein Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
D-T7 Peptide-Modified PEGylated Bilirubin Nanoparticles Loaded with Cediranib and Paclitaxel for Antiangiogenesis and Chemotherapy of Glioma.
Topics: Animals; Bilirubin; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Collagen Type IV; Drug Carriers; Glioma; Humans; Male; Mice; Nanoparticles; Paclitaxel; Peptide Fragments; Quinazolines | 2019 |
Phosphoinositide-3-kinase inhibition elevates ferritin level resulting depletion of labile iron pool and blocking of glioma cell proliferation.
Topics: Adenine; Animals; Brain Neoplasms; Cell Proliferation; Cells, Cultured; Chromones; Down-Regulation; Ferritins; Glioma; Humans; Iron; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pyrimidinones; Quinazolines; Rats; Thiazolidinediones; Up-Regulation | 2019 |
Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
Topics: Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutagenesis, Insertional; Quinazolines; Sequence Deletion | 2019 |
Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Drug Discovery; Humans; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2019 |
Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
Topics: Acrylamides; Adenocarcinoma of Lung; Aged; Alleles; Amino Acid Substitution; Aniline Compounds; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Combined Modality Therapy; Crown Ethers; ErbB Receptors; Humans; Magnetic Resonance Imaging; Male; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retreatment; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2019 |
For breast cancer patients with brain mets, new drug combo may be option.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Treatment Outcome | 2012 |
Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Gefitinib; Glioma; Humans; Photochemotherapy; Photosensitizing Agents; Quinazolines; Treatment Outcome | 2013 |
[A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.
Topics: AC133 Antigen; Adolescent; Adult; Animals; Antigens, CD; Antineoplastic Agents; Brain Neoplasms; Drug Resistance; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Glioblastoma; Glycoproteins; Humans; Immunohistochemistry; Immunomagnetic Separation; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Peptides; Quinazolines; Real-Time Polymerase Chain Reaction; Stem Cells; Young Adult | 2013 |
Radiological response of brain metastases to novel tyrosine kinase inhibitor lapatinib.
Topics: Brain Neoplasms; Female; Humans; Lapatinib; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
A multi-parametric imaging investigation of the response of C6 glioma xenografts to MLN0518 (tandutinib) treatment.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Contrast Media; Diagnostic Imaging; Diffusion Magnetic Resonance Imaging; Female; Glioma; Humans; Mice; Mice, Nude; Piperazines; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2013 |
In regard to Chakravarti et al.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Quinazolines | 2013 |
Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Capillary Permeability; Cell Line, Tumor; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Glioblastoma; Humans; Male; Mice; Mice, Nude; Phosphorylation; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Humans; Intracranial Hypertension; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Middle Aged; Molecular Targeted Therapy; Quinazolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2013 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT & SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320: in regard to Sperduto
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Dacarbazine; Humans; Lung Neoplasms; Quinazolines; Radiosurgery | 2013 |
In reply to Robins et al.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Dacarbazine; Humans; Lung Neoplasms; Quinazolines; Radiosurgery | 2013 |
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Topics: Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Forkhead Transcription Factors; Gene Amplification; Glioblastoma; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2013 |
Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and non-small-cell lung cancer?
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
[Current possibilities of targeted therapy in the treatment of breast cancer with overexpression of HER-2/neu and metastatic lesions in the brain].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Up-Regulation | 2013 |
SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Blotting, Western; Brain; Brain Neoplasms; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cells, Cultured; Electric Impedance; Endothelium, Vascular; ErbB Receptors; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lapatinib; Mice; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; src-Family Kinases; Xenograft Model Antitumor Assays | 2013 |
Reply to v.R. Bhatt et Al and m.C. Chamberlain.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines | 2013 |
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Topics: Animals; Anoikis; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Brain Neoplasms; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Indoles; Lapatinib; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2013 |
Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging.
Topics: Animals; Antineoplastic Agents; Biomarkers; Blood-Brain Barrier; Brain Neoplasms; Disease Models, Animal; Erlotinib Hydrochloride; Glioma; Heme; Heterografts; Humans; Mice; Molecular Imaging; Neovascularization, Pathologic; Optical Imaging; Permeability; Pharmaceutical Preparations; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2013 |
Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2013 |
Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Failure | 2014 |
In vivo behavior and safety of lapatinib-incorporated lipid nanoparticles.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Glioma; Injections, Intravenous; Lapatinib; Lethal Dose 50; Lipids; Male; Mice, Inbred ICR; Nanoparticles; Organ Specificity; Particle Size; Quinazolines; Rats, Sprague-Dawley; Solubility; Surface Properties; Tablets; Tissue Distribution | 2014 |
Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2014 |
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2014 |
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Brain Neoplasms; Cranial Irradiation; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2014 |
Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
Topics: AC133 Antigen; Antigens, CD; Azepines; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioma; Glycoproteins; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Histones; Humans; Lysine; Methylation; Neoplastic Stem Cells; Peptides; Promoter Regions, Genetic; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Transfection | 2014 |
The effects of selected inhibitors of histone modifying enzyme on C6 glioma cells.
Topics: Acetylation; Adenosine; Animals; Azepines; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Epigenesis, Genetic; Glioma; Histones; Hydroxamic Acids; Piperazines; Quinazolines; Rats; Valproic Acid | 2014 |
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Protein; Beclin-1; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Drug Synergism; ErbB Receptors; fas Receptor; Fas-Associated Death Domain Protein; Glioblastoma; Humans; Lapatinib; Lysosomal-Associated Membrane Protein 2; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Quinazolines; Sorafenib; TOR Serine-Threonine Kinases; Unfolded Protein Response | 2015 |
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Brain Chemistry; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Prospective Studies; Quinazolines | 2015 |
Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
Topics: Adult; Afatinib; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression; Glioblastoma; Humans; Lapatinib; Mice; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
Topics: Animals; Brain Neoplasms; Cell Movement; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Receptors, Urokinase Plasminogen Activator; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Tumor Cells, Cultured | 2015 |
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Outcome Assessment, Health Care; Prognosis; Quinazolines; Temozolomide; Young Adult | 2015 |
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glioblastoma; Heterografts; Humans; Membrane Proteins; Mice; Mice, Nude; Proto-Oncogene Proteins; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction | 2015 |
Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Enzyme Activation; Glioma; Mice; Proto-Oncogene Proteins c-akt; Quinacrine; Quinazolines; Vacuoles | 2014 |
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2015 |
Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cell Proliferation; Central Nervous System; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2 | 2015 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Gene Knockdown Techniques; Glucuronidase; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The evidence of glioblastoma heterogeneity.
Topics: Animals; Antigens, CD; Brain Neoplasms; Collagen Type I; Collagen Type I, alpha 1 Chain; Disease Models, Animal; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Insulin-Like Growth Factor Binding Proteins; Kaplan-Meier Estimate; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured | 2015 |
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Benzylamines; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cyclams; Female; Glioblastoma; Heterocyclic Compounds; Humans; Interleukin-2 Receptor alpha Subunit; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neoplasm Invasiveness; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, CXCR4; Receptors, Transforming Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Clinical Trials as Topic; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2015 |
Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.
Topics: Aurora Kinase B; Brain Neoplasms; Caspase 3; Cell Cycle; Cell Death; Cell Division; Cell Line, Tumor; Cell Shape; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Micronucleus, Germline; Mutation; Organophosphates; Polyploidy; Protein Kinase Inhibitors; Quinazolines; Transcription, Genetic; Tumor Stem Cell Assay | 2016 |
Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Young Adult | 2015 |
[Brain metastases in pulmonary adenocarcinoma with EGFR mutation: how important is therapy with erlotinib compared to radiotherapy?].
Topics: Adenocarcinoma; Brain Neoplasms; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2015 |
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
Topics: Animals; Brain Neoplasms; Crizotinib; Cyclin-Dependent Kinase Inhibitor p16; Doxycycline; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Processing, Post-Translational; PTEN Phosphohydrolase; Pyrazoles; Pyridines; Quinazolines; Quinolines; Tumor Cells, Cultured | 2015 |
ROS1 amplification mediates resistance to gefitinib in glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Drug Synergism; Gefitinib; Gene Amplification; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinazolines; S Phase | 2015 |
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Gene Amplification; Gene Rearrangement; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neuroimaging; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Receptor, ErbB-2; Retreatment; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2015 |
Highly sensitive HPLC-DAD method for the assay of gefitinib in patient plasma and cerebrospinal fluid: application to a blood-brain barrier penetration study.
Topics: Blood-Brain Barrier; Brain Neoplasms; Chromatography, High Pressure Liquid; Gefitinib; Humans; Linear Models; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction | 2015 |
Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Comorbidity; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Radiosurgery; Retrospective Studies; Taiwan; Treatment Outcome | 2015 |
Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI?
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2015 |
[A Case of Effective Whole-Brain Irradiation and Lapatinib/Capecitabine Combination Therapy for HER2-Positive Breast Cancer with Multiple Brain Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2015 |
Depot delivery of dexamethasone and cediranib for the treatment of brain tumor associated edema in an intracranial rat glioma model.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Brain Neoplasms; Cells, Cultured; Dexamethasone; Drug Delivery Systems; Drug Liberation; Edema; Female; Glioma; Human Umbilical Vein Endothelial Cells; Protein Kinase Inhibitors; Quinazolines; Rats, Inbred F344 | 2015 |
Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Capillary Permeability; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neurons; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Topics: Animals; Brain; Brain Neoplasms; Central Nervous System; Clinical Trials, Phase I as Topic; Dogs; Drug Discovery; ErbB Receptors; Macaca fascicularis; Male; Mice; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Wistar; Xenograft Model Antitumor Assays | 2015 |
Modulatory Effects of Curcumin and Tyrphostins (AG494 and AG1478) on Growth Regulation and Viability of LN229 Human Brain Cancer Cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcumin; DNA Damage; ErbB Receptors; Humans; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Tyrphostins | 2015 |
[Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Brain Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; DNA Breaks, Double-Stranded; DNA Repair; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Microscopy, Fluorescence; Quinazolines; Radiation Tolerance; Signal Transduction; X-Rays | 2015 |
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Female; Genotype; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Proteins v-erbB; Quinazolines; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome | 2015 |
Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Aptamers, Nucleotide; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Immunoenzyme Techniques; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Phosphorylation; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2015 |
Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.
Topics: Adenocarcinoma; Afatinib; Brain Neoplasms; Diagnostic Imaging; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab | 2015 |
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Topics: Afatinib; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2016 |
Better treatments needed for breast cancer brain metastases.
Topics: Afatinib; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Female; Humans; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2015 |
Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Glioma; Mice; Quinazolines; Semicarbazones | 2015 |
Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Remission Induction | 2016 |
Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.
Topics: Animals; Brain Neoplasms; Carbazoles; DNA-Binding Proteins; Glioblastoma; High Mobility Group Proteins; Humans; Lapatinib; Mice; Quinazolines; Transcriptional Elongation Factors | 2016 |
Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Drug Carriers; Drug Compounding; Drug Stability; Female; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Phosphatidylcholines; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Tissue Distribution; Triple Negative Breast Neoplasms | 2016 |
Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromones; Doxazosin; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Glycogen Synthase Kinase 3 beta; Hippocampus; Humans; Lapatinib; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Wistar; Tumor Suppressor Protein p53 | 2016 |
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Madin Darby Canine Kidney Cells; Male; Mice; Mice, SCID; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2016 |
Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2016 |
β-Elemene enhances the efficacy of gefitinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Quinazolines; Sesquiterpenes; Signal Transduction | 2016 |
Case-specific potentiation of glioblastoma drugs by pterostilbene.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Copy Number Variations; Drug Synergism; Female; Gefitinib; Gene Expression Profiling; Gene Knockdown Techniques; Glioblastoma; Humans; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Stilbenes; Transcriptome | 2016 |
Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
Topics: Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Central Nervous System Neoplasms; Disease Models, Animal; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spinal Cord | 2016 |
BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells.
Topics: Autophagy; Azepines; Brain Neoplasms; Cell Differentiation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glioblastoma; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Humans; Neoplastic Stem Cells; Quinazolines; Tumor Cells, Cultured | 2016 |
Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2017 |
Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma.
Topics: Animals; Astrocytes; Brain; Brain Neoplasms; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Down-Regulation; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Grading; Oligodendrocyte Transcription Factor 2; Plasmids; Plicamycin; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; RNA Interference; SOXB1 Transcription Factors; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.
Topics: AC133 Antigen; Animals; Brain Neoplasms; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Embryo, Mammalian; Enzyme Inhibitors; Female; Gefitinib; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Naphthyridines; Neoplastic Stem Cells; Phenazines; Pregnancy; Quinazolines; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Brain Neoplasms; Breast Neoplasms; Cranial Irradiation; ErbB Receptors; Female; Humans; Lapatinib; Metastasectomy; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Trastuzumab | 2017 |
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells.
Topics: Anoikis; Antineoplastic Agents; Brain Neoplasms; Cell Adhesion; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Gefitinib; Glioblastoma; Humans; Neovascularization, Pathologic; Phenylurea Compounds; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glioblastoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; PTEN Phosphohydrolase; Quinazolines | 2008 |
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines | 2008 |
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Brain Neoplasms; Carcinoma, Bronchogenic; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Risk Assessment | 2008 |
As metastasis yields its biological secrets, researchers hope to apply findings.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Denosumab; Drug Design; ErbB Receptors; Female; Humans; Lapatinib; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Quinazolines; RANK Ligand; Receptor, ErbB-2; Trastuzumab | 2008 |
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoblotting; Immunochemistry; Lapatinib; Mice; Mice, Inbred BALB C; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; RNA, Small Interfering; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Cyclin D1; DNA, Complementary; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoblotting; Immunoprecipitation; Neoplasms; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Repressor Proteins; RNA, Small Interfering; Sequence Analysis, DNA; Signal Transduction | 2008 |
Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; DNA Damage; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitory Concentration 50; Janus Kinase 2; Mice; Quinazolines; STAT3 Transcription Factor | 2008 |
Are volumetric changes of brain metastases the best evaluation of efficacy?
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cranial Irradiation; Endpoint Determination; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Research Design; Treatment Outcome | 2008 |
[Molecular imaging of epidermal growth factor receptor in glioma-bearing rats].
Topics: Animals; Brain Neoplasms; Carbon Radioisotopes; Cell Line, Tumor; ErbB Receptors; Gastrointestinal Tract; Glioma; Liver; Male; Neoplasm Transplantation; Positron-Emission Tomography; Quinazolines; Rats; Rats, Wistar; Tissue Distribution; Tomography, X-Ray Computed | 2008 |
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carbazoles; Clinical Trials as Topic; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Remission Induction; Smoking | 2009 |
New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Child; Child, Preschool; Ependymoma; Erlotinib Hydrochloride; Gefitinib; Humans; Infant; Quinazolines; Treatment Outcome; Young Adult | 2009 |
A case report of thyroid cancer showing a remarkable effect of gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Papillary; Female; Gefitinib; Head and Neck Neoplasms; Humans; Incidental Findings; Lung Neoplasms; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model.
Topics: Animals; Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Disease Models, Animal; Ferric Compounds; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
Topics: Animals; Antineoplastic Agents; Brain Edema; Brain Neoplasms; Glioblastoma; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Magnetic Resonance Imaging; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2009 |
Unilateral taxane-induced onychopathy in a patient with a brain metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carboplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Fluorouracil; Hand; Humans; Lapatinib; Middle Aged; Onycholysis; Paclitaxel; Paresis; Peripheral Nervous System Diseases; Quinazolines; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.
Topics: Astrocytoma; Brain Neoplasms; Cellulase; Corneal Diseases; Corneal Opacity; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ointments; Piperidines; Quinazolines; Retrospective Studies; Sodium Chloride; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?
Topics: Animals; Antineoplastic Agents; Astrocytes; Benzamides; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cerebral Cortex; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kinesins; Quinazolines; Rats; Spindle Apparatus | 2009 |
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Topics: Antineoplastic Agents; Biomarkers; Blood Volume; Brain Neoplasms; Collagen; Disease-Free Survival; Glioblastoma; Hematologic Tests; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Predictive Value of Tests; Quinazolines; Survival Rate | 2009 |
Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Exons; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2009 |
Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature.
Topics: Biological Availability; Brain Neoplasms; Child; Combined Modality Therapy; Cystic Fibrosis; Erlotinib Hydrochloride; Exocrine Pancreatic Insufficiency; Female; Glioma; Humans; Malabsorption Syndromes; Pancrelipase; Protein Kinase Inhibitors; Quinazolines | 2009 |
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Hepatocyte Growth Factor; Immunoblotting; Immunoenzyme Techniques; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cysts; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2009 |
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spinal Cord Neoplasms; Treatment Outcome | 2009 |
Modeling glioma growth and invasion in Drosophila melanogaster.
Topics: Animals; Brain Neoplasms; Drosophila melanogaster; ErbB Receptors; Eye; Gefitinib; Glioma; Humans; Immunoenzyme Techniques; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured | 2009 |
[A case of non-small cell lung cancer treated safely by whole brain radiation therapy and erlotinib].
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2009 |
[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2009 |
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Fatty Acids; Gene Knockdown Techniques; Glioblastoma; Humans; Hydrolysis; Lapatinib; Lipogenesis; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; Sterol Regulatory Element Binding Protein 1 | 2009 |
[Successful gefitinib every other day administration in an advanced lung cancer patient with brain metastasis after gamma knife radiotherapy and chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Radiosurgery | 2009 |
New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung.
Topics: Aged; Biopsy; Brain Neoplasms; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pneumonia; Quinazolines; Tomography, X-Ray Computed | 2011 |
[Lung cancer: an update in 2010].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Small Cell Lung Carcinoma | 2010 |
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; DNA Transposable Elements; ErbB Receptors; Female; Gefitinib; Genetic Variation; Glioblastoma; Humans; Mitochondria; Proto-Oncogene Proteins; Quinazolines; Sequence Deletion; Transplantation, Heterologous | 2010 |
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Health Services Accessibility; Humans; Lapatinib; Middle Aged; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
[Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Interstitial infusion of erlotinib in the rodent brain.
Topics: Animals; Body Weight; Brain; Brain Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Microinjections; Neostriatum; Quinazolines; Rats; Rats, Nude | 2009 |
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome; Whole-Body Irradiation | 2010 |
A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Databases, Factual; Erlotinib Hydrochloride; Humans; Indoles; Middle Aged; Neoplasms; Prognosis; Pyrroles; Quinazolines; Severity of Illness Index; Sunitinib; Trastuzumab | 2010 |
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Neurilemmoma; Neurofibromatosis 2; Neurofibromin 2; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2010 |
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Goiter, Nodular; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Radiotherapy | 2010 |
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Folliculitis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2010 |
Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Administration Schedule; ErbB Receptors; Glioma; Multivariate Analysis; Nerve Tissue Proteins; Piperidines; Protein Kinase Inhibitors; Proteomics; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Time Factors | 2010 |
Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.
Topics: Animals; Blotting, Western; Bone Neoplasms; Brain Neoplasms; Humans; Immunoenzyme Techniques; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Quinazolines; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Electromyography; Female; Glioblastoma; Humans; Male; Middle Aged; Myasthenia Gravis; Neuromuscular Diseases; Neuromuscular Junction; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Syndrome | 2011 |
[Pleural metastases from bronchial carcinoma: is a cure possible?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperidines; Pleural Neoplasms; Quinazolines; Radiotherapy; Receptor Protein-Tyrosine Kinases; Retreatment; Survivors; Thoracotomy | 2011 |
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer.
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Mastectomy; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Skin Neoplasms | 2011 |
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pyrroles; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide | 2011 |
Epithelial growth factor receptor tyrosine kinase inhibitor prevents infiltration and cerebrospinal fluid dissemination in malignant glioma: an experimental study.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cadherins; Cell Line; Enzyme Inhibitors; ErbB Receptors; Glioma; Male; Neoplasms, Experimental; Quinazolines; Rats; Rats, Sprague-Dawley; Tyrphostins; Up-Regulation | 2011 |
Cediranib enhances control of wild type EGFR and EGFRvIII-expressing gliomas through potentiating temozolomide, but not through radiosensitization: implications for the clinic.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Survival; Dacarbazine; ErbB Receptors; Glioma; Humans; Immunoblotting; Mice; Mice, Nude; Quinazolines; Radiation Tolerance; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A; X-Rays | 2011 |
[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2011 |
[Antitumor effects of gefitinib for metastatic brain tumors from lung carcinomas with EGFR mutation].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2011 |
Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung.
Topics: Brain Neoplasms; Breath Tests; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Exhalation; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Remission Induction; Sequence Deletion; Smoking | 2011 |
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gefitinib; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Models, Biological; Phenylbutyrates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Stem Cell Assay | 2011 |
Recovery from carcinomatous meningitis by erlotinib.
Topics: Adenocarcinoma; Aged; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Gefitinib; Glioma; Humans; Immunoprecipitation; Membrane Potential, Mitochondrial; Phosphorylation; Quinazolines; RNA, Small Interfering; Transfection | 2011 |
Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.
Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Compounding; ErbB Receptors; Erlotinib Hydrochloride; Gene Silencing; Glioblastoma; Humans; Hydroxamic Acids; Ligands; Neoplasm Proteins; Particle Size; PC12 Cells; Quinazolines; Rats; RNA, Small Interfering; Vorinostat | 2011 |
Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemical Fractionation; Child; Chromatography, Liquid; Drug Stability; Humans; Piperidines; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mutation; Quinazolines; Radionuclide Imaging | 2011 |
Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2011 |
Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Ligands; Membrane Proteins; Mice; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2011 |
Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Radiography | 2011 |
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Glioblastoma; Humans; Kaplan-Meier Estimate; Mice; Mice, SCID; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Injections, Intravenous; Lapatinib; Mice; Quinazolines; Receptor, ErbB-2; Up-Regulation | 2012 |
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bcl-2-Like Protein 11; Beclin-1; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Glioma; Heterocyclic Compounds, 3-Ring; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell Death; Cholesterol; ErbB Receptors; Glioblastoma; HeLa Cells; Humans; Lapatinib; Liver X Receptors; Mice; Mice, SCID; Orphan Nuclear Receptors; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, LDL; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Up-Regulation | 2011 |
[Complete remission of multiple brain metastases of non-small cell lung cancer induced by gefitinib monotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain Neoplasms; Cranial Irradiation; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Staging; Quinazolines; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2011 |
Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Radiation-Sensitizing Agents; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Temozolomide; Time Factors | 2012 |
EGFR inhibitor enhances cisplatin sensitivity of human glioma cells.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Glioma; Humans; Protein Tyrosine Phosphatases; Quinazolines; Tyrphostins | 2011 |
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Glioma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Rate; Tumor Cells, Cultured; Young Adult | 2012 |
Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2012 |
The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
[Evaluation of gefitinib plus radiotherapy in non-small-cell lung cancer patients with brain metastases].
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Breaks, Double-Stranded; DNA-Activated Protein Kinase; ErbB Receptors; Gefitinib; Glioma; Histones; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Neuroglia; Phosphorylation; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Stem Cell Assay | 2012 |
Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Occupy EGFR.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Kinetics; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
[A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Hydrocephalus; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Ventriculoperitoneal Shunt | 2012 |
Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Multivariate Analysis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Turkey | 2012 |
Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tandem Mass Spectrometry | 2013 |
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chromatography, Liquid; Gefitinib; Glioblastoma; Mice; Models, Biological; Quinazolines; Tandem Mass Spectrometry | 2012 |
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Topics: Animals; Astrocytes; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Mice, Mutant Strains; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine | 2012 |
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult | 2012 |
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Cystadenocarcinoma, Mucinous; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Factors; Survival Rate | 2012 |
OSU-03012 interacts with lapatinib to kill brain cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; Beclin-1; Benzoquinones; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Genes, erbB-1; Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Lipids; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides | 2012 |
Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Disease Models, Animal; Drug Interactions; Female; Glioblastoma; Humans; Immunohistochemistry; Intermediate Filament Proteins; Macrophages; Mice; Mice, Inbred C57BL; Mice, Nude; Nerve Tissue Proteins; Nestin; Pyrazoles; Pyrimidines; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2012 |
Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Female; Gefitinib; Glioblastoma; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Rats, Inbred F344; Spheroids, Cellular; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Erlotinib-induced bullous pemphigoid.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Pemphigoid, Bullous; Quinazolines | 2012 |
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Brain Neoplasms; Breast Neoplasms; Cell Death; Cell Proliferation; Diagnostic Imaging; Disease Models, Animal; Female; Gene Amplification; Humans; Killer Cells, Natural; Lapatinib; Mice; Molecular Targeted Therapy; Necrosis; Neovascularization, Pathologic; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Neoplastic Stem Cells; Quinazolines; Veratrum Alkaloids | 2012 |
Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Glioblastoma; Humans; Male; Mice; Mice, SCID; Neoplasm Invasiveness; p38 Mitogen-Activated Protein Kinases; Protein Array Analysis; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2013 |
Primary systemic treatment of breast-cancer brain metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Middle Aged; Mutation, Missense; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
[A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Remission Induction | 2012 |
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Combined Modality Therapy; Crizotinib; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Young Adult | 2012 |
HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Humans; Injections, Intravenous; Kidney Neoplasms; Lapatinib; Male; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2012 |
Response to: "rare serious complications of erlotinib therapy".
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Brain metastases from HER2-positive breast cancer - authors' reply.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines | 2013 |
Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Keratin-7; Lung; Lung Neoplasms; Middle Aged; Mutation; Nuclear Proteins; Protein Kinase Inhibitors; Quinazolines; Thyroid Nuclear Factor 1; Time Factors; Transcription Factors; Treatment Outcome | 2013 |
Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Quinazolines; Radiosurgery; Receptor, ErbB-2; Retrospective Studies; Survival Rate | 2013 |
Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dacarbazine; Drug Synergism; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Rare serious complications of erlotinib therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
Topics: 3T3 Cells; Administration, Oral; Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Tumor Cells, Cultured; Tyrosine | 2002 |
A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Quinazolines; Treatment Outcome | 2003 |
ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Division; Cerebellum; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Phosphorylation; Placenta; Quinazolines; Radiation-Sensitizing Agents; Radiation, Ionizing; Radiotherapy Dosage; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Targeting HER2 in brain metastases from breast cancer.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Rats; Rats, Nude; Receptor, ErbB-2 | 2003 |
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Division; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Glioma; Humans; Mice; Mice, Inbred BALB C; Naphthalenes; NIH 3T3 Cells; Oncogene Proteins v-erbB; Phosphoinositide-3 Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Signal Transduction; Transduction, Genetic; Xenograft Model Antitumor Assays | 2003 |
Effect of gefitinib (ZD1839) on metastatic brain tumour.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Treatment Outcome | 2004 |
Gefitinib in recurrent glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Endpoint Determination; Epidermal Growth Factor; Gefitinib; Glioblastoma; Humans; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results | 2004 |
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Division; Disease Models, Animal; Enzyme Inhibitors; Glioma; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Rats | 2004 |
[Recurrence of non-small cell lung cancer after successful treatment with gefitinib--report of three cases].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis.
Topics: Apoptosis; Brain Neoplasms; Caspase 8; Caspases; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Fas Ligand Protein; Glioma; Humans; Membrane Glycoproteins; Quinazolines; Receptor, IGF Type 1; Ribosomal Protein S6; Signal Transduction; Tumor Suppressor Protein p53; Tyrphostins | 2004 |
EGFR mutations and sensitivity to gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
Topics: Angiogenesis Inhibitors; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Melanoma; Mice; Mice, Inbred BALB C; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Oligonucleotides, Antisense; Phenotype; Piperidines; Placebos; Quinazolines; RNA; Transfection; Treatment Outcome; Vascular Endothelial Growth Factor A | 2004 |
Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Somatic mutations of EGFR in colorectal cancers and glioblastomas.
Topics: Brain Neoplasms; Colorectal Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Glioblastoma; Point Mutation; Quinazolines | 2004 |
Innovative therapy for patients with brain metastases: oral treatments.
Topics: Administration, Oral; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Quinazolines; Temozolomide | 2004 |
Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Failure | 2005 |
EGFR tyrosine kinase domain mutations in human gliomas.
Topics: Astrocytoma; Brain Neoplasms; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Oligodendroglioma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines | 2005 |
Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report.
Topics: Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2005 |
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
[A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quinazolines; Remission Induction; Retreatment; Tomography, X-Ray Computed | 2005 |
Complete response to erlotinib treatment in brain metastases from recurrent NSCLC.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2006 |
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Quinazolines | 2006 |
Gefitinib accumulation in glioblastoma tissue.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mass Spectrometry; Quinazolines | 2006 |
Evolution of management strategies for cerebral gliomas: the effects of science and technology.
Topics: Antibiotics, Antineoplastic; Brain Neoplasms; DNA Repair; DNA-Binding Proteins; Doxorubicin; Endonucleases; Erlotinib Hydrochloride; Gene Silencing; Genes, erbB-1; Genome, Human; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Xeroderma Pigmentosum Group D Protein | 2005 |
Erlotinib induced skin rash spares skin in previous radiotherapy field.
Topics: Adenocarcinoma; Back; Brain Neoplasms; Chemotherapy, Adjuvant; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Reoperation; Skin; Thoracic Wall | 2006 |
Influence of whole-brain radiotherapy on remission of brain metastases.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Time Factors; Treatment Outcome | 2006 |
Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Risk Factors | 2006 |
Gefitinib concentrations in human glioblastoma tissue.
Topics: Antineoplastic Agents; Biological Availability; Brain Neoplasms; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Quinazolines | 2007 |
[Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years].
Topics: Adenocarcinoma, Papillary; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiotherapy Dosage; Survivors | 2006 |
Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Skin Diseases, Vesiculobullous | 2006 |
Effect of gefitinib on brain metastases from non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2006 |
Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Topics: Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Densitometry; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; Glioblastoma; Humans; In Situ Nick-End Labeling; Indicators and Reagents; Mutation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Signal Transduction; Topotecan; Tumor Suppressor Protein p53 | 2007 |
[Gefitinib in the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Recurrent responses to non-small cell lung cancer brain metastases with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Quinazolines | 2006 |
[A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Radiosurgery; Remission Induction; Smoking | 2007 |
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Piperidines; Pulmonary Embolism; Quinazolines; Skin Neoplasms; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2007 |
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Survival Rate; Xenograft Model Antitumor Assays | 2007 |
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quinazolines; Retrospective Studies; Treatment Outcome | 2007 |
Significant drug interaction: phenytoin toxicity due to erlotinib.
Topics: Anticonvulsants; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Phenytoin; Protein Kinase Inhibitors; Quinazolines; Seizures | 2007 |
Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
Topics: Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2006 |
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germ-Line Mutation; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Survival Rate | 2008 |
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer.
Topics: Brain Neoplasms; Erlotinib Hydrochloride; Fatal Outcome; Hematoma, Subdural; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis | 2008 |
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Indoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Signal Transduction; Sulfonamides | 2007 |
CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; DNA Fragmentation; Drug Administration Schedule; Endothelium, Vascular; ErbB Receptors; Gefitinib; Glioma; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Receptor, ErbB-2 | 2007 |
Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2007 |
Response of intracranial metastases to erlotinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2007 |
Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Humans; Mice; Mice, Nude; Mice, SCID; Morpholines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2008 |
Erosive pustular dermatosis of the scalp after gefitinib and radiotherapy for brain metastases secondary to lung cancer.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Gefitinib; Humans; Quinazolines; Radiotherapy; Scalp Dermatoses | 2008 |
Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Blood-Brain Barrier; Brain Neoplasms; Contrast Media; Dextrans; Ferrosoferric Oxide; Gadolinium DTPA; Glioma; Immunohistochemistry; Iron; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Microcirculation; Oxides; Piperidines; Predictive Value of Tests; Quinazolines; Transplantation, Heterologous | 2008 |
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Humans; Mice; Neovascularization, Pathologic; Piperidines; Quinazolines; Temozolomide; Xenograft Model Antitumor Assays | 2008 |
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aza Compounds; Brain Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mutation; Promoter Regions, Genetic; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA Interference; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Suppressor Protein p53; Up-Regulation; Valine | 2008 |
[Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Vomiting | 2007 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; ErbB Receptors; Glioma; Neoplasm Transplantation; Piperidines; Quinazolines; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide | 2008 |
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2008 |
Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells.
Topics: AC133 Antigen; Antigens, CD; Brain Neoplasms; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Models, Biological; Peptides; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Stem Cells; Tumor Cells, Cultured; Tyrphostins | 2008 |
Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2008 |
EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Enzyme Activation; Ependymoma; ErbB Receptors; Female; Flow Cytometry; G1 Phase; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Situ Nick-End Labeling; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2008 |
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Candidiasis; Cell Division; Cell Line; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Mice, SCID; Models, Molecular; Molecular Conformation; Molecular Structure; Molecular Weight; Pneumonia, Pneumocystis; Protein Structure, Secondary; Quinazolines; Structure-Activity Relationship; Toxoplasma; Tumor Cells, Cultured | 1996 |
4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dose-Response Relationship, Drug; Epidermal Growth Factor; Glioblastoma; Humans; Mice; Mice, SCID; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
Topics: Animals; Brain Neoplasms; Cell Survival; Cisplatin; Enzyme Inhibitors; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Transplantation; Protein Tyrosine Phosphatases; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrphostins | 2001 |
CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Brain Neoplasms; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cell Survival; Coumarins; Cycloheximide; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Fas Ligand Protein; Fluorescent Dyes; Gene Expression Regulation, Neoplastic; Glioma; Humans; Membrane Glycoproteins; Oligopeptides; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Serpins; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tyrphostins; Viral Proteins | 2002 |
Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Topics: 3T3 Cells; Animals; Brain Neoplasms; Cell Division; Cell Survival; Glioblastoma; Humans; Ligands; Lymphokines; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Receptors, Platelet-Derived Growth Factor; Signal Transduction | 2002 |